{"id": "F1.1-000001", "family_id": "F1.1", "template_id": "f1_1_targets_gene", "question": "What drugs target PSMD12?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('PSMD12')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('PSMD12'))\nRETURN\n  t.name AS therapy_name,\n  g.symbol AS gene_symbol,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"therapy_name": "Bortezomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "21606441"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "http://europepmc.org/abstract/MED/21606441"]}, {"therapy_name": "Carfilzomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["FDA", "PubMed"], "ref_ids": ["label/2012/202714lbl.pdf", "20116451"], "ref_urls": ["http://europepmc.org/abstract/MED/20116451", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf"]}, {"therapy_name": "Ixazomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteasome inhibitor", "ref_sources": ["EMA", "PubMed", "PubMed"], "ref_ids": ["https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf", "23995855", "30867233"], "ref_urls": ["http://europepmc.org/abstract/MED/23995855", "http://europepmc.org/abstract/MED/30867233", "https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf"]}], "error": null}
{"id": "F1.1-000001-P1", "family_id": "F1.1", "template_id": "f1_1_targets_gene", "question": "Which therapies target PSMD12?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('PSMD12')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('PSMD12'))\nRETURN\n  t.name AS therapy_name,\n  g.symbol AS gene_symbol,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"therapy_name": "Bortezomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "21606441"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "http://europepmc.org/abstract/MED/21606441"]}, {"therapy_name": "Carfilzomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["FDA", "PubMed"], "ref_ids": ["label/2012/202714lbl.pdf", "20116451"], "ref_urls": ["http://europepmc.org/abstract/MED/20116451", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf"]}, {"therapy_name": "Ixazomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteasome inhibitor", "ref_sources": ["EMA", "PubMed", "PubMed"], "ref_ids": ["https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf", "23995855", "30867233"], "ref_urls": ["http://europepmc.org/abstract/MED/23995855", "http://europepmc.org/abstract/MED/30867233", "https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf"]}], "error": null}
{"id": "F1.1-000001-P2", "family_id": "F1.1", "template_id": "f1_1_targets_gene", "question": "List treatments that target PSMD12.", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('PSMD12')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('PSMD12'))\nRETURN\n  t.name AS therapy_name,\n  g.symbol AS gene_symbol,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"therapy_name": "Bortezomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "21606441"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "http://europepmc.org/abstract/MED/21606441"]}, {"therapy_name": "Carfilzomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["FDA", "PubMed"], "ref_ids": ["label/2012/202714lbl.pdf", "20116451"], "ref_urls": ["http://europepmc.org/abstract/MED/20116451", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf"]}, {"therapy_name": "Ixazomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteasome inhibitor", "ref_sources": ["EMA", "PubMed", "PubMed"], "ref_ids": ["https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf", "23995855", "30867233"], "ref_urls": ["http://europepmc.org/abstract/MED/23995855", "http://europepmc.org/abstract/MED/30867233", "https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf"]}], "error": null}
{"id": "F1.1-000001-P3", "family_id": "F1.1", "template_id": "f1_1_targets_gene", "question": "What medications are known to target PSMD12?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('PSMD12')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('PSMD12'))\nRETURN\n  t.name AS therapy_name,\n  g.symbol AS gene_symbol,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"therapy_name": "Bortezomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "21606441"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "http://europepmc.org/abstract/MED/21606441"]}, {"therapy_name": "Carfilzomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["FDA", "PubMed"], "ref_ids": ["label/2012/202714lbl.pdf", "20116451"], "ref_urls": ["http://europepmc.org/abstract/MED/20116451", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf"]}, {"therapy_name": "Ixazomib", "gene_symbol": "PSMD12", "targets_moa": "26S proteasome inhibitor", "ref_sources": ["EMA", "PubMed", "PubMed"], "ref_ids": ["https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf", "23995855", "30867233"], "ref_urls": ["http://europepmc.org/abstract/MED/23995855", "http://europepmc.org/abstract/MED/30867233", "https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf"]}], "error": null}
{"id": "F1.2-000001", "family_id": "F1.2", "template_id": "f1_2_genes_for_therapy", "question": "Which genes does BRAF Inhibitor target?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(t.name) = toLower('BRAF Inhibitor')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('BRAF Inhibitor'))\n  OR toLower(t.name) CONTAINS toLower('BRAF Inhibitor')\n)\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "therapy_name": "BRAF Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}], "error": null}
{"id": "F1.2-000001-P1", "family_id": "F1.2", "template_id": "f1_2_genes_for_therapy", "question": "What genes does BRAF Inhibitor target?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(t.name) = toLower('BRAF Inhibitor')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('BRAF Inhibitor'))\n  OR toLower(t.name) CONTAINS toLower('BRAF Inhibitor')\n)\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "therapy_name": "BRAF Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}], "error": null}
{"id": "F1.2-000001-P2", "family_id": "F1.2", "template_id": "f1_2_genes_for_therapy", "question": "List genes that BRAF Inhibitor targets.", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(t.name) = toLower('BRAF Inhibitor')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('BRAF Inhibitor'))\n  OR toLower(t.name) CONTAINS toLower('BRAF Inhibitor')\n)\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "therapy_name": "BRAF Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}], "error": null}
{"id": "F1.2-000001-P3", "family_id": "F1.2", "template_id": "f1_2_genes_for_therapy", "question": "Which genes are targeted by BRAF Inhibitor?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(t.name) = toLower('BRAF Inhibitor')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('BRAF Inhibitor'))\n  OR toLower(t.name) CONTAINS toLower('BRAF Inhibitor')\n)\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "therapy_name": "BRAF Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}], "error": null}
{"id": "F1.3-000001", "family_id": "F1.3", "template_id": "f1_3_gene_of_variant", "question": "Which gene is BRAF V600E a variant of?", "cypher": "MATCH (v:Variant {name: 'BRAF V600E'})-[:VARIANT_OF]->(g:Gene)\nRETURN g.symbol AS gene_symbol, v.name AS variant_name\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "variant_name": "BRAF V600E"}], "error": null}
{"id": "F1.3-000001-P1", "family_id": "F1.3", "template_id": "f1_3_gene_of_variant", "question": "BRAF V600E belongs to which gene?", "cypher": "MATCH (v:Variant {name: 'BRAF V600E'})-[:VARIANT_OF]->(g:Gene)\nRETURN g.symbol AS gene_symbol, v.name AS variant_name\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "variant_name": "BRAF V600E"}], "error": null}
{"id": "F1.3-000001-P2", "family_id": "F1.3", "template_id": "f1_3_gene_of_variant", "question": "BRAF V600E is a variant of what gene?", "cypher": "MATCH (v:Variant {name: 'BRAF V600E'})-[:VARIANT_OF]->(g:Gene)\nRETURN g.symbol AS gene_symbol, v.name AS variant_name\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "variant_name": "BRAF V600E"}], "error": null}
{"id": "F1.3-000001-P3", "family_id": "F1.3", "template_id": "f1_3_gene_of_variant", "question": "Identify the gene for the variant BRAF V600E.", "cypher": "MATCH (v:Variant {name: 'BRAF V600E'})-[:VARIANT_OF]->(g:Gene)\nRETURN g.symbol AS gene_symbol, v.name AS variant_name\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "variant_name": "BRAF V600E"}], "error": null}
{"id": "F1.4-000001", "family_id": "F1.4", "template_id": "f1_4_variants_of_gene", "question": "List all known variants of the RARG gene.", "cypher": "MATCH (v:Variant)-[:VARIANT_OF]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('RARG')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('RARG'))\nRETURN v.name AS variant_name, g.symbol AS gene_symbol\nLIMIT 100\n", "result": [], "error": null}
{"id": "F1.4-000001-P1", "family_id": "F1.4", "template_id": "f1_4_variants_of_gene", "question": "What variants are known for the RARG gene?", "cypher": "MATCH (v:Variant)-[:VARIANT_OF]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('RARG')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('RARG'))\nRETURN v.name AS variant_name, g.symbol AS gene_symbol\nLIMIT 100\n", "result": [], "error": null}
{"id": "F1.4-000001-P2", "family_id": "F1.4", "template_id": "f1_4_variants_of_gene", "question": "Show the variants associated with RARG.", "cypher": "MATCH (v:Variant)-[:VARIANT_OF]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('RARG')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('RARG'))\nRETURN v.name AS variant_name, g.symbol AS gene_symbol\nLIMIT 100\n", "result": [], "error": null}
{"id": "F1.4-000001-P3", "family_id": "F1.4", "template_id": "f1_4_variants_of_gene", "question": "Which variants belong to the gene RARG?", "cypher": "MATCH (v:Variant)-[:VARIANT_OF]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('RARG')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('RARG'))\nRETURN v.name AS variant_name, g.symbol AS gene_symbol\nLIMIT 100\n", "result": [], "error": null}
{"id": "F2.1-000001", "family_id": "F2.1", "template_id": "f2_1_targets_properties", "question": "What is Valproic Acid's mechanism of action on ALDH5A1?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(t.name) = toLower('Valproic Acid')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Valproic Acid'))\n  OR toLower(t.name) CONTAINS toLower('Valproic Acid')\n)\n  AND (\n    toLower(g.symbol) = toLower('ALDH5A1')\n    OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ALDH5A1'))\n  )\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "ALDH5A1", "therapy_name": "Valproic Acid", "targets_moa": "Succinate semialdehyde dehydrogenase inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["10812195"], "ref_urls": ["http://europepmc.org/abstract/MED/10812195"]}], "error": null}
{"id": "F2.1-000001-P1", "family_id": "F2.1", "template_id": "f2_1_targets_properties", "question": "What is the MOA of Valproic Acid on ALDH5A1?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(t.name) = toLower('Valproic Acid')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Valproic Acid'))\n  OR toLower(t.name) CONTAINS toLower('Valproic Acid')\n)\n  AND (\n    toLower(g.symbol) = toLower('ALDH5A1')\n    OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ALDH5A1'))\n  )\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "ALDH5A1", "therapy_name": "Valproic Acid", "targets_moa": "Succinate semialdehyde dehydrogenase inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["10812195"], "ref_urls": ["http://europepmc.org/abstract/MED/10812195"]}], "error": null}
{"id": "F2.1-000001-P2", "family_id": "F2.1", "template_id": "f2_1_targets_properties", "question": "Describe how Valproic Acid acts on ALDH5A1.", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(t.name) = toLower('Valproic Acid')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Valproic Acid'))\n  OR toLower(t.name) CONTAINS toLower('Valproic Acid')\n)\n  AND (\n    toLower(g.symbol) = toLower('ALDH5A1')\n    OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ALDH5A1'))\n  )\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "ALDH5A1", "therapy_name": "Valproic Acid", "targets_moa": "Succinate semialdehyde dehydrogenase inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["10812195"], "ref_urls": ["http://europepmc.org/abstract/MED/10812195"]}], "error": null}
{"id": "F2.1-000001-P3", "family_id": "F2.1", "template_id": "f2_1_targets_properties", "question": "What is Valproic Acid's mechanism against ALDH5A1?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(t.name) = toLower('Valproic Acid')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Valproic Acid'))\n  OR toLower(t.name) CONTAINS toLower('Valproic Acid')\n)\n  AND (\n    toLower(g.symbol) = toLower('ALDH5A1')\n    OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ALDH5A1'))\n  )\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "ALDH5A1", "therapy_name": "Valproic Acid", "targets_moa": "Succinate semialdehyde dehydrogenase inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["10812195"], "ref_urls": ["http://europepmc.org/abstract/MED/10812195"]}], "error": null}
{"id": "F2.2-000001", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease", "question": "Which genes affect response to Immune Checkpoint Inhibitor in Lung Non-small Cell Carcinoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Immune Checkpoint Inhibitor')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Immune Checkpoint Inhibitor'))\n  OR toLower(t.name) CONTAINS toLower('Immune Checkpoint Inhibitor')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  NULL AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "Immune Checkpoint Inhibitor", "effect": null, "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28259530"]}], "error": null}
{"id": "F2.2-000001-P1", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease", "question": "What genes are predictive biomarkers for Immune Checkpoint Inhibitor in Lung Non-small Cell Carcinoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Immune Checkpoint Inhibitor')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Immune Checkpoint Inhibitor'))\n  OR toLower(t.name) CONTAINS toLower('Immune Checkpoint Inhibitor')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  NULL AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "Immune Checkpoint Inhibitor", "effect": null, "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28259530"]}], "error": null}
{"id": "F2.2-000001-P2", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease", "question": "Which genes influence response to Immune Checkpoint Inhibitor for Lung Non-small Cell Carcinoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Immune Checkpoint Inhibitor')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Immune Checkpoint Inhibitor'))\n  OR toLower(t.name) CONTAINS toLower('Immune Checkpoint Inhibitor')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  NULL AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "Immune Checkpoint Inhibitor", "effect": null, "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28259530"]}], "error": null}
{"id": "F2.2-000001-P3", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease", "question": "List genes with evidence affecting Immune Checkpoint Inhibitor in Lung Non-small Cell Carcinoma.", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Immune Checkpoint Inhibitor')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Immune Checkpoint Inhibitor'))\n  OR toLower(t.name) CONTAINS toLower('Immune Checkpoint Inhibitor')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  NULL AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "Immune Checkpoint Inhibitor", "effect": null, "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28259530"]}], "error": null}
{"id": "F2.2-000001", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease_resistance", "question": "Which genes predict resistance to Regorafenib Anhydrous in Colorectal Cancer?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Regorafenib Anhydrous')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Regorafenib Anhydrous'))\n  OR toLower(t.name) CONTAINS toLower('Regorafenib Anhydrous')\n)\nAND toLower(rel.effect) = 'resistance'\nAND (\n    toLower(rel.disease_name) CONTAINS 'colorectal'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'resistance' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "FBXW7", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["27399335"]}, {"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["26161928", "26870193"]}, {"variant_name": null, "gene_symbol": "PIK3CA", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["26184520"]}], "error": null}
{"id": "F2.2-000001-P1", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease_resistance", "question": "Which genes confer resistance to Regorafenib Anhydrous in Colorectal Cancer?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Regorafenib Anhydrous')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Regorafenib Anhydrous'))\n  OR toLower(t.name) CONTAINS toLower('Regorafenib Anhydrous')\n)\nAND toLower(rel.effect) = 'resistance'\nAND (\n    toLower(rel.disease_name) CONTAINS 'colorectal'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'resistance' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "FBXW7", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["27399335"]}, {"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["26161928", "26870193"]}, {"variant_name": null, "gene_symbol": "PIK3CA", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["26184520"]}], "error": null}
{"id": "F2.2-000001-P2", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease_resistance", "question": "List genes associated with resistance to Regorafenib Anhydrous in Colorectal Cancer.", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Regorafenib Anhydrous')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Regorafenib Anhydrous'))\n  OR toLower(t.name) CONTAINS toLower('Regorafenib Anhydrous')\n)\nAND toLower(rel.effect) = 'resistance'\nAND (\n    toLower(rel.disease_name) CONTAINS 'colorectal'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'resistance' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "FBXW7", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["27399335"]}, {"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["26161928", "26870193"]}, {"variant_name": null, "gene_symbol": "PIK3CA", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["26184520"]}], "error": null}
{"id": "F2.2-000001-P3", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease_resistance", "question": "What genes are resistance biomarkers for Regorafenib Anhydrous in Colorectal Cancer?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Regorafenib Anhydrous')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Regorafenib Anhydrous'))\n  OR toLower(t.name) CONTAINS toLower('Regorafenib Anhydrous')\n)\nAND toLower(rel.effect) = 'resistance'\nAND (\n    toLower(rel.disease_name) CONTAINS 'colorectal'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'resistance' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "FBXW7", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["27399335"]}, {"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["26161928", "26870193"]}, {"variant_name": null, "gene_symbol": "PIK3CA", "therapy_name": "Regorafenib Anhydrous", "effect": "resistance", "disease_name": "Colorectal Cancer", "pmids": ["26184520"]}], "error": null}
{"id": "F2.2-000001", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease_sensitivity", "question": "Which genes predict sensitivity to Selumetinib in Malignant Astrocytoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Selumetinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Selumetinib'))\n  OR toLower(t.name) CONTAINS toLower('Selumetinib')\n)\nAND toLower(rel.effect) = 'sensitivity'\nAND (\n    toLower(rel.disease_name) CONTAINS 'malignant' AND\n    toLower(rel.disease_name) CONTAINS 'astrocytoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'sensitivity' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "NF1", "therapy_name": "Selumetinib", "effect": "sensitivity", "disease_name": "Malignant Astrocytoma", "pmids": ["35945463"]}], "error": null}
{"id": "F2.2-000001-P1", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease_sensitivity", "question": "Which genes confer sensitivity to Selumetinib in Malignant Astrocytoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Selumetinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Selumetinib'))\n  OR toLower(t.name) CONTAINS toLower('Selumetinib')\n)\nAND toLower(rel.effect) = 'sensitivity'\nAND (\n    toLower(rel.disease_name) CONTAINS 'malignant' AND\n    toLower(rel.disease_name) CONTAINS 'astrocytoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'sensitivity' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "NF1", "therapy_name": "Selumetinib", "effect": "sensitivity", "disease_name": "Malignant Astrocytoma", "pmids": ["35945463"]}], "error": null}
{"id": "F2.2-000001-P2", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease_sensitivity", "question": "List genes associated with sensitivity to Selumetinib in Malignant Astrocytoma.", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Selumetinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Selumetinib'))\n  OR toLower(t.name) CONTAINS toLower('Selumetinib')\n)\nAND toLower(rel.effect) = 'sensitivity'\nAND (\n    toLower(rel.disease_name) CONTAINS 'malignant' AND\n    toLower(rel.disease_name) CONTAINS 'astrocytoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'sensitivity' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "NF1", "therapy_name": "Selumetinib", "effect": "sensitivity", "disease_name": "Malignant Astrocytoma", "pmids": ["35945463"]}], "error": null}
{"id": "F2.2-000001-P3", "family_id": "F2.2", "template_id": "f2_2_gene_affects_therapy_disease_sensitivity", "question": "What genes are sensitivity biomarkers for Selumetinib in Malignant Astrocytoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Selumetinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Selumetinib'))\n  OR toLower(t.name) CONTAINS toLower('Selumetinib')\n)\nAND toLower(rel.effect) = 'sensitivity'\nAND (\n    toLower(rel.disease_name) CONTAINS 'malignant' AND\n    toLower(rel.disease_name) CONTAINS 'astrocytoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'sensitivity' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "NF1", "therapy_name": "Selumetinib", "effect": "sensitivity", "disease_name": "Malignant Astrocytoma", "pmids": ["35945463"]}], "error": null}
{"id": "F2.2-000001", "family_id": "F2.2", "template_id": "f2_2_variant_affects_therapy_disease", "question": "How does the variant NRAS Q61K affect response to Everolimus in Neuroblastoma?", "cypher": "MATCH (v:Variant {name: 'NRAS Q61K'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Everolimus')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Everolimus'))\n  OR toLower(t.name) CONTAINS toLower('Everolimus')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'neuroblastoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "NRAS Q61K", "gene_symbol": "NRAS", "therapy_name": "Everolimus", "effect": "sensitivity", "disease_name": "Neuroblastoma", "pmids": ["26821351"]}], "error": null}
{"id": "F2.2-000001-P1", "family_id": "F2.2", "template_id": "f2_2_variant_affects_therapy_disease", "question": "What is the effect of NRAS Q61K on Everolimus in Neuroblastoma?", "cypher": "MATCH (v:Variant {name: 'NRAS Q61K'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Everolimus')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Everolimus'))\n  OR toLower(t.name) CONTAINS toLower('Everolimus')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'neuroblastoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "NRAS Q61K", "gene_symbol": "NRAS", "therapy_name": "Everolimus", "effect": "sensitivity", "disease_name": "Neuroblastoma", "pmids": ["26821351"]}], "error": null}
{"id": "F2.2-000001-P2", "family_id": "F2.2", "template_id": "f2_2_variant_affects_therapy_disease", "question": "Does NRAS Q61K predict response to Everolimus in Neuroblastoma?", "cypher": "MATCH (v:Variant {name: 'NRAS Q61K'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Everolimus')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Everolimus'))\n  OR toLower(t.name) CONTAINS toLower('Everolimus')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'neuroblastoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "NRAS Q61K", "gene_symbol": "NRAS", "therapy_name": "Everolimus", "effect": "sensitivity", "disease_name": "Neuroblastoma", "pmids": ["26821351"]}], "error": null}
{"id": "F2.2-000001-P3", "family_id": "F2.2", "template_id": "f2_2_variant_affects_therapy_disease", "question": "How does NRAS Q61K influence response to Everolimus for Neuroblastoma?", "cypher": "MATCH (v:Variant {name: 'NRAS Q61K'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Everolimus')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Everolimus'))\n  OR toLower(t.name) CONTAINS toLower('Everolimus')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'neuroblastoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "NRAS Q61K", "gene_symbol": "NRAS", "therapy_name": "Everolimus", "effect": "sensitivity", "disease_name": "Neuroblastoma", "pmids": ["26821351"]}], "error": null}
{"id": "F2.2-000001", "family_id": "F2.2", "template_id": "f2_2_variant_token_affects_therapy_disease", "question": "How does the variant ABL1 R351W affect response to Imatinib in Lung Non-small Cell Carcinoma?", "cypher": "MATCH (v:Variant {name: 'ABL1 R351W'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Imatinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Imatinib'))\n  OR toLower(t.name) CONTAINS toLower('Imatinib')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "ABL1 R351W", "gene_symbol": "ABL1", "therapy_name": "Imatinib", "effect": "sensitivity", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["26758680"]}], "error": null}
{"id": "F2.2-000001-P1", "family_id": "F2.2", "template_id": "f2_2_variant_token_affects_therapy_disease", "question": "What is the effect of ABL1 R351W on Imatinib in Lung Non-small Cell Carcinoma?", "cypher": "MATCH (v:Variant {name: 'ABL1 R351W'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Imatinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Imatinib'))\n  OR toLower(t.name) CONTAINS toLower('Imatinib')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "ABL1 R351W", "gene_symbol": "ABL1", "therapy_name": "Imatinib", "effect": "sensitivity", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["26758680"]}], "error": null}
{"id": "F2.2-000001-P2", "family_id": "F2.2", "template_id": "f2_2_variant_token_affects_therapy_disease", "question": "Does ABL1 R351W predict response to Imatinib in Lung Non-small Cell Carcinoma?", "cypher": "MATCH (v:Variant {name: 'ABL1 R351W'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Imatinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Imatinib'))\n  OR toLower(t.name) CONTAINS toLower('Imatinib')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "ABL1 R351W", "gene_symbol": "ABL1", "therapy_name": "Imatinib", "effect": "sensitivity", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["26758680"]}], "error": null}
{"id": "F2.2-000001-P3", "family_id": "F2.2", "template_id": "f2_2_variant_token_affects_therapy_disease", "question": "How does ABL1 R351W influence response to Imatinib for Lung Non-small Cell Carcinoma?", "cypher": "MATCH (v:Variant {name: 'ABL1 R351W'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Imatinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Imatinib'))\n  OR toLower(t.name) CONTAINS toLower('Imatinib')\n)\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "ABL1 R351W", "gene_symbol": "ABL1", "therapy_name": "Imatinib", "effect": "sensitivity", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["26758680"]}], "error": null}
{"id": "F2.3-000001", "family_id": "F2.3", "template_id": "f2_3_evidential_pmids_variant_resistance", "question": "Provide PMIDs supporting that BCR BCR::ABL1 Fusion AND ABL1 L384M confers resistance to Nilotinib.", "cypher": "MATCH (v:Variant {name: 'BCR BCR::ABL1 Fusion AND ABL1 L384M'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Nilotinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Nilotinib'))\n  OR toLower(t.name) CONTAINS toLower('Nilotinib')\n)\nAND toLower(rel.effect) = 'resistance'\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'resistance' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "BCR BCR::ABL1 Fusion AND ABL1 L384M", "gene_symbol": "BCR", "therapy_name": "Nilotinib", "effect": "resistance", "disease_name": "Chronic Myeloid Leukemia", "pmids": ["16772610"]}], "error": null}
{"id": "F2.3-000001-P1", "family_id": "F2.3", "template_id": "f2_3_evidential_pmids_variant_resistance", "question": "Cite PubMed IDs showing BCR BCR::ABL1 Fusion AND ABL1 L384M causes resistance to Nilotinib.", "cypher": "MATCH (v:Variant {name: 'BCR BCR::ABL1 Fusion AND ABL1 L384M'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Nilotinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Nilotinib'))\n  OR toLower(t.name) CONTAINS toLower('Nilotinib')\n)\nAND toLower(rel.effect) = 'resistance'\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'resistance' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "BCR BCR::ABL1 Fusion AND ABL1 L384M", "gene_symbol": "BCR", "therapy_name": "Nilotinib", "effect": "resistance", "disease_name": "Chronic Myeloid Leukemia", "pmids": ["16772610"]}], "error": null}
{"id": "F2.3-000001-P2", "family_id": "F2.3", "template_id": "f2_3_evidential_pmids_variant_resistance", "question": "What PMIDs support resistance of Nilotinib due to BCR BCR::ABL1 Fusion AND ABL1 L384M?", "cypher": "MATCH (v:Variant {name: 'BCR BCR::ABL1 Fusion AND ABL1 L384M'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Nilotinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Nilotinib'))\n  OR toLower(t.name) CONTAINS toLower('Nilotinib')\n)\nAND toLower(rel.effect) = 'resistance'\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'resistance' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "BCR BCR::ABL1 Fusion AND ABL1 L384M", "gene_symbol": "BCR", "therapy_name": "Nilotinib", "effect": "resistance", "disease_name": "Chronic Myeloid Leukemia", "pmids": ["16772610"]}], "error": null}
{"id": "F2.3-000001-P3", "family_id": "F2.3", "template_id": "f2_3_evidential_pmids_variant_resistance", "question": "Give PMIDs for BCR BCR::ABL1 Fusion AND ABL1 L384M-mediated resistance to Nilotinib.", "cypher": "MATCH (v:Variant {name: 'BCR BCR::ABL1 Fusion AND ABL1 L384M'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Nilotinib')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Nilotinib'))\n  OR toLower(t.name) CONTAINS toLower('Nilotinib')\n)\nAND toLower(rel.effect) = 'resistance'\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'resistance' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "BCR BCR::ABL1 Fusion AND ABL1 L384M", "gene_symbol": "BCR", "therapy_name": "Nilotinib", "effect": "resistance", "disease_name": "Chronic Myeloid Leukemia", "pmids": ["16772610"]}], "error": null}
{"id": "F2.3-000001", "family_id": "F2.3", "template_id": "f2_3_evidential_pmids_variant_sensitivity", "question": "Provide PMIDs supporting that ERBB2 Overexpression confers sensitivity to Capecitabine.", "cypher": "MATCH (v:Variant {name: 'ERBB2 Overexpression'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Capecitabine')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Capecitabine'))\n  OR toLower(t.name) CONTAINS toLower('Capecitabine')\n)\nAND toLower(rel.effect) = 'sensitivity'\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'sensitivity' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "ERBB2 Overexpression", "gene_symbol": "ERBB2", "therapy_name": "Capecitabine", "effect": "sensitivity", "disease_name": "Pancreatic Cancer", "pmids": ["22374460"]}, {"variant_name": "ERBB2 Overexpression", "gene_symbol": "ERBB2", "therapy_name": "Capecitabine", "effect": "sensitivity", "disease_name": "Salivary Gland Cancer", "pmids": ["20504363"]}], "error": null}
{"id": "F2.3-000001-P1", "family_id": "F2.3", "template_id": "f2_3_evidential_pmids_variant_sensitivity", "question": "Cite PMIDs showing ERBB2 Overexpression predicts sensitivity to Capecitabine.", "cypher": "MATCH (v:Variant {name: 'ERBB2 Overexpression'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Capecitabine')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Capecitabine'))\n  OR toLower(t.name) CONTAINS toLower('Capecitabine')\n)\nAND toLower(rel.effect) = 'sensitivity'\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'sensitivity' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "ERBB2 Overexpression", "gene_symbol": "ERBB2", "therapy_name": "Capecitabine", "effect": "sensitivity", "disease_name": "Pancreatic Cancer", "pmids": ["22374460"]}, {"variant_name": "ERBB2 Overexpression", "gene_symbol": "ERBB2", "therapy_name": "Capecitabine", "effect": "sensitivity", "disease_name": "Salivary Gland Cancer", "pmids": ["20504363"]}], "error": null}
{"id": "F2.3-000001-P2", "family_id": "F2.3", "template_id": "f2_3_evidential_pmids_variant_sensitivity", "question": "What PubMed IDs support sensitivity of Capecitabine due to ERBB2 Overexpression?", "cypher": "MATCH (v:Variant {name: 'ERBB2 Overexpression'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Capecitabine')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Capecitabine'))\n  OR toLower(t.name) CONTAINS toLower('Capecitabine')\n)\nAND toLower(rel.effect) = 'sensitivity'\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'sensitivity' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "ERBB2 Overexpression", "gene_symbol": "ERBB2", "therapy_name": "Capecitabine", "effect": "sensitivity", "disease_name": "Pancreatic Cancer", "pmids": ["22374460"]}, {"variant_name": "ERBB2 Overexpression", "gene_symbol": "ERBB2", "therapy_name": "Capecitabine", "effect": "sensitivity", "disease_name": "Salivary Gland Cancer", "pmids": ["20504363"]}], "error": null}
{"id": "F2.3-000001-P3", "family_id": "F2.3", "template_id": "f2_3_evidential_pmids_variant_sensitivity", "question": "Give PMIDs for ERBB2 Overexpression-mediated sensitivity to Capecitabine.", "cypher": "MATCH (v:Variant {name: 'ERBB2 Overexpression'})-[:VARIANT_OF]->(g:Gene)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('Capecitabine')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('Capecitabine'))\n  OR toLower(t.name) CONTAINS toLower('Capecitabine')\n)\nAND toLower(rel.effect) = 'sensitivity'\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'sensitivity' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "ERBB2 Overexpression", "gene_symbol": "ERBB2", "therapy_name": "Capecitabine", "effect": "sensitivity", "disease_name": "Pancreatic Cancer", "pmids": ["22374460"]}, {"variant_name": "ERBB2 Overexpression", "gene_symbol": "ERBB2", "therapy_name": "Capecitabine", "effect": "sensitivity", "disease_name": "Salivary Gland Cancer", "pmids": ["20504363"]}], "error": null}
{"id": "F2.4-000001", "family_id": "F2.4", "template_id": "f2_4_variant_node_property", "question": "What is the consequence of the BRAF V600E variant?", "cypher": "MATCH (v:Variant {name: 'BRAF V600E'})\nRETURN\n  v.name AS variant_name,\n  v.consequence AS variant_consequence\nLIMIT 100\n", "result": [{"variant_name": "BRAF V600E", "variant_consequence": null}], "error": null}
{"id": "F2.4-000001-P1", "family_id": "F2.4", "template_id": "f2_4_variant_node_property", "question": "What consequence does the variant BRAF V600E have?", "cypher": "MATCH (v:Variant {name: 'BRAF V600E'})\nRETURN\n  v.name AS variant_name,\n  v.consequence AS variant_consequence\nLIMIT 100\n", "result": [{"variant_name": "BRAF V600E", "variant_consequence": null}], "error": null}
{"id": "F2.4-000001-P2", "family_id": "F2.4", "template_id": "f2_4_variant_node_property", "question": "Report the consequence for BRAF V600E.", "cypher": "MATCH (v:Variant {name: 'BRAF V600E'})\nRETURN\n  v.name AS variant_name,\n  v.consequence AS variant_consequence\nLIMIT 100\n", "result": [{"variant_name": "BRAF V600E", "variant_consequence": null}], "error": null}
{"id": "F2.4-000001-P3", "family_id": "F2.4", "template_id": "f2_4_variant_node_property", "question": "What is the functional consequence of BRAF V600E?", "cypher": "MATCH (v:Variant {name: 'BRAF V600E'})\nRETURN\n  v.name AS variant_name,\n  v.consequence AS variant_consequence\nLIMIT 100\n", "result": [{"variant_name": "BRAF V600E", "variant_consequence": null}], "error": null}
{"id": "F3.1-000001", "family_id": "F3.1", "template_id": "f3_1_therapies_union_genes", "question": "Find therapies for ABL1 or ADRM1.", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(g.symbol) = toLower('ABL1')\n  OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ABL1'))\n  OR toLower(g.symbol) = toLower('ADRM1')\n  OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ADRM1'))\n)\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "ABL1", "therapy_name": "Asciminib", "targets_moa": "Bcr/Abl fusion protein inhibitor | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["FDA", "Other", "Other"], "ref_ids": ["label/2021/215358s000Orig1lbl.pdf", "http://www.bloodjournal.org/content/124/21/398?sso-checked=true", "http://www.novartisoncology.com/ct/pipelineDetails?compound=ABL001&diseaseAcr=CML"], "ref_urls": ["http://www.bloodjournal.org/content/124/21/398?sso-checked=true", "http://www.novartisoncology.com/ct/pipelineDetails?compound=ABL001&diseaseAcr=CML", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Bafetinib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["16105974"], "ref_urls": ["http://europepmc.org/abstract/MED/16105974"]}, {"gene_symbol": "ABL1", "therapy_name": "Bosutinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["BOSUTINIB", "label/2012/203341lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=BOSUTINIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Dasatinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA"], "ref_ids": ["setid=0e7f054c-7a27-4192-bd1c-6115d8be858f#section-13", "label/2010/021986s7s8lbl.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f#section-13", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Imatinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA", "Wikipedia"], "ref_ids": ["setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "label/2008/021588s024lbl.pdf", "Bcr-Abl_tyrosine-kinase_inhibitor"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Imatinib Mesylate", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA", "Wikipedia"], "ref_ids": ["setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "label/2008/021588s024lbl.pdf", "Bcr-Abl_tyrosine-kinase_inhibitor"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Nilotinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA"], "ref_ids": ["setid=6093952a-5248-45cb-ad17-33716a411146#section-13", "label/2010/022068s004s005lbl.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6093952a-5248-45cb-ad17-33716a411146#section-13", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Ponatinib", "targets_moa": "Bcr/Abl fusion protein inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=807f988e-117b-4497-934d-73aa78baac71", "19878872"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=807f988e-117b-4497-934d-73aa78baac71", "http://europepmc.org/abstract/MED/19878872"]}, {"gene_symbol": "ABL1", "therapy_name": "Rebastinib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21481795"], "ref_urls": ["http://europepmc.org/abstract/MED/21481795"]}, {"gene_symbol": "ABL1", "therapy_name": "Regorafenib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Regorafenib Anhydrous", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "TRK Inhibitor", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ADRM1", "therapy_name": "Bortezomib", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "21606441"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "http://europepmc.org/abstract/MED/21606441"]}, {"gene_symbol": "ADRM1", "therapy_name": "Carfilzomib", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["FDA", "PubMed"], "ref_ids": ["label/2012/202714lbl.pdf", "20116451"], "ref_urls": ["http://europepmc.org/abstract/MED/20116451", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf"]}, {"gene_symbol": "ADRM1", "therapy_name": "Ixazomib", "targets_moa": "26S proteasome inhibitor", "ref_sources": ["EMA", "PubMed", "PubMed"], "ref_ids": ["https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf", "23995855", "30867233"], "ref_urls": ["http://europepmc.org/abstract/MED/23995855", "http://europepmc.org/abstract/MED/30867233", "https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf"]}], "error": null}
{"id": "F3.1-000001-P1", "family_id": "F3.1", "template_id": "f3_1_therapies_union_genes", "question": "Which therapies target ABL1 or ADRM1?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(g.symbol) = toLower('ABL1')\n  OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ABL1'))\n  OR toLower(g.symbol) = toLower('ADRM1')\n  OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ADRM1'))\n)\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "ABL1", "therapy_name": "Asciminib", "targets_moa": "Bcr/Abl fusion protein inhibitor | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["FDA", "Other", "Other"], "ref_ids": ["label/2021/215358s000Orig1lbl.pdf", "http://www.bloodjournal.org/content/124/21/398?sso-checked=true", "http://www.novartisoncology.com/ct/pipelineDetails?compound=ABL001&diseaseAcr=CML"], "ref_urls": ["http://www.bloodjournal.org/content/124/21/398?sso-checked=true", "http://www.novartisoncology.com/ct/pipelineDetails?compound=ABL001&diseaseAcr=CML", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Bafetinib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["16105974"], "ref_urls": ["http://europepmc.org/abstract/MED/16105974"]}, {"gene_symbol": "ABL1", "therapy_name": "Bosutinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["BOSUTINIB", "label/2012/203341lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=BOSUTINIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Dasatinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA"], "ref_ids": ["setid=0e7f054c-7a27-4192-bd1c-6115d8be858f#section-13", "label/2010/021986s7s8lbl.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f#section-13", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Imatinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA", "Wikipedia"], "ref_ids": ["setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "label/2008/021588s024lbl.pdf", "Bcr-Abl_tyrosine-kinase_inhibitor"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Imatinib Mesylate", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA", "Wikipedia"], "ref_ids": ["setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "label/2008/021588s024lbl.pdf", "Bcr-Abl_tyrosine-kinase_inhibitor"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Nilotinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA"], "ref_ids": ["setid=6093952a-5248-45cb-ad17-33716a411146#section-13", "label/2010/022068s004s005lbl.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6093952a-5248-45cb-ad17-33716a411146#section-13", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Ponatinib", "targets_moa": "Bcr/Abl fusion protein inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=807f988e-117b-4497-934d-73aa78baac71", "19878872"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=807f988e-117b-4497-934d-73aa78baac71", "http://europepmc.org/abstract/MED/19878872"]}, {"gene_symbol": "ABL1", "therapy_name": "Rebastinib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21481795"], "ref_urls": ["http://europepmc.org/abstract/MED/21481795"]}, {"gene_symbol": "ABL1", "therapy_name": "Regorafenib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Regorafenib Anhydrous", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "TRK Inhibitor", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ADRM1", "therapy_name": "Bortezomib", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "21606441"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "http://europepmc.org/abstract/MED/21606441"]}, {"gene_symbol": "ADRM1", "therapy_name": "Carfilzomib", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["FDA", "PubMed"], "ref_ids": ["label/2012/202714lbl.pdf", "20116451"], "ref_urls": ["http://europepmc.org/abstract/MED/20116451", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf"]}, {"gene_symbol": "ADRM1", "therapy_name": "Ixazomib", "targets_moa": "26S proteasome inhibitor", "ref_sources": ["EMA", "PubMed", "PubMed"], "ref_ids": ["https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf", "23995855", "30867233"], "ref_urls": ["http://europepmc.org/abstract/MED/23995855", "http://europepmc.org/abstract/MED/30867233", "https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf"]}], "error": null}
{"id": "F3.1-000001-P2", "family_id": "F3.1", "template_id": "f3_1_therapies_union_genes", "question": "List drugs for ABL1 or ADRM1.", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(g.symbol) = toLower('ABL1')\n  OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ABL1'))\n  OR toLower(g.symbol) = toLower('ADRM1')\n  OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ADRM1'))\n)\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "ABL1", "therapy_name": "Asciminib", "targets_moa": "Bcr/Abl fusion protein inhibitor | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["FDA", "Other", "Other"], "ref_ids": ["label/2021/215358s000Orig1lbl.pdf", "http://www.bloodjournal.org/content/124/21/398?sso-checked=true", "http://www.novartisoncology.com/ct/pipelineDetails?compound=ABL001&diseaseAcr=CML"], "ref_urls": ["http://www.bloodjournal.org/content/124/21/398?sso-checked=true", "http://www.novartisoncology.com/ct/pipelineDetails?compound=ABL001&diseaseAcr=CML", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Bafetinib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["16105974"], "ref_urls": ["http://europepmc.org/abstract/MED/16105974"]}, {"gene_symbol": "ABL1", "therapy_name": "Bosutinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["BOSUTINIB", "label/2012/203341lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=BOSUTINIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Dasatinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA"], "ref_ids": ["setid=0e7f054c-7a27-4192-bd1c-6115d8be858f#section-13", "label/2010/021986s7s8lbl.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f#section-13", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Imatinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA", "Wikipedia"], "ref_ids": ["setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "label/2008/021588s024lbl.pdf", "Bcr-Abl_tyrosine-kinase_inhibitor"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Imatinib Mesylate", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA", "Wikipedia"], "ref_ids": ["setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "label/2008/021588s024lbl.pdf", "Bcr-Abl_tyrosine-kinase_inhibitor"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Nilotinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA"], "ref_ids": ["setid=6093952a-5248-45cb-ad17-33716a411146#section-13", "label/2010/022068s004s005lbl.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6093952a-5248-45cb-ad17-33716a411146#section-13", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Ponatinib", "targets_moa": "Bcr/Abl fusion protein inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=807f988e-117b-4497-934d-73aa78baac71", "19878872"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=807f988e-117b-4497-934d-73aa78baac71", "http://europepmc.org/abstract/MED/19878872"]}, {"gene_symbol": "ABL1", "therapy_name": "Rebastinib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21481795"], "ref_urls": ["http://europepmc.org/abstract/MED/21481795"]}, {"gene_symbol": "ABL1", "therapy_name": "Regorafenib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Regorafenib Anhydrous", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "TRK Inhibitor", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ADRM1", "therapy_name": "Bortezomib", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "21606441"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "http://europepmc.org/abstract/MED/21606441"]}, {"gene_symbol": "ADRM1", "therapy_name": "Carfilzomib", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["FDA", "PubMed"], "ref_ids": ["label/2012/202714lbl.pdf", "20116451"], "ref_urls": ["http://europepmc.org/abstract/MED/20116451", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf"]}, {"gene_symbol": "ADRM1", "therapy_name": "Ixazomib", "targets_moa": "26S proteasome inhibitor", "ref_sources": ["EMA", "PubMed", "PubMed"], "ref_ids": ["https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf", "23995855", "30867233"], "ref_urls": ["http://europepmc.org/abstract/MED/23995855", "http://europepmc.org/abstract/MED/30867233", "https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf"]}], "error": null}
{"id": "F3.1-000001-P3", "family_id": "F3.1", "template_id": "f3_1_therapies_union_genes", "question": "Show treatments that target ABL1 or ADRM1.", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(g:Gene)\nWHERE (\n  toLower(g.symbol) = toLower('ABL1')\n  OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ABL1'))\n  OR toLower(g.symbol) = toLower('ADRM1')\n  OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('ADRM1'))\n)\nRETURN\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "ABL1", "therapy_name": "Asciminib", "targets_moa": "Bcr/Abl fusion protein inhibitor | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["FDA", "Other", "Other"], "ref_ids": ["label/2021/215358s000Orig1lbl.pdf", "http://www.bloodjournal.org/content/124/21/398?sso-checked=true", "http://www.novartisoncology.com/ct/pipelineDetails?compound=ABL001&diseaseAcr=CML"], "ref_urls": ["http://www.bloodjournal.org/content/124/21/398?sso-checked=true", "http://www.novartisoncology.com/ct/pipelineDetails?compound=ABL001&diseaseAcr=CML", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Bafetinib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["16105974"], "ref_urls": ["http://europepmc.org/abstract/MED/16105974"]}, {"gene_symbol": "ABL1", "therapy_name": "Bosutinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["BOSUTINIB", "label/2012/203341lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=BOSUTINIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Dasatinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA"], "ref_ids": ["setid=0e7f054c-7a27-4192-bd1c-6115d8be858f#section-13", "label/2010/021986s7s8lbl.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f#section-13", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Imatinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA", "Wikipedia"], "ref_ids": ["setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "label/2008/021588s024lbl.pdf", "Bcr-Abl_tyrosine-kinase_inhibitor"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Imatinib Mesylate", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA", "Wikipedia"], "ref_ids": ["setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "label/2008/021588s024lbl.pdf", "Bcr-Abl_tyrosine-kinase_inhibitor"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Nilotinib", "targets_moa": "Bcr/Abl fusion protein | Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["DailyMed", "FDA"], "ref_ids": ["setid=6093952a-5248-45cb-ad17-33716a411146#section-13", "label/2010/022068s004s005lbl.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6093952a-5248-45cb-ad17-33716a411146#section-13", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Ponatinib", "targets_moa": "Bcr/Abl fusion protein inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=807f988e-117b-4497-934d-73aa78baac71", "19878872"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=807f988e-117b-4497-934d-73aa78baac71", "http://europepmc.org/abstract/MED/19878872"]}, {"gene_symbol": "ABL1", "therapy_name": "Rebastinib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21481795"], "ref_urls": ["http://europepmc.org/abstract/MED/21481795"]}, {"gene_symbol": "ABL1", "therapy_name": "Regorafenib", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "Regorafenib Anhydrous", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ABL1", "therapy_name": "TRK Inhibitor", "targets_moa": "Tyrosine-protein kinase ABL inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "ADRM1", "therapy_name": "Bortezomib", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["DailyMed", "PubMed"], "ref_ids": ["setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "21606441"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7#section-13", "http://europepmc.org/abstract/MED/21606441"]}, {"gene_symbol": "ADRM1", "therapy_name": "Carfilzomib", "targets_moa": "26S proteosome inhibitor", "ref_sources": ["FDA", "PubMed"], "ref_ids": ["label/2012/202714lbl.pdf", "20116451"], "ref_urls": ["http://europepmc.org/abstract/MED/20116451", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf"]}, {"gene_symbol": "ADRM1", "therapy_name": "Ixazomib", "targets_moa": "26S proteasome inhibitor", "ref_sources": ["EMA", "PubMed", "PubMed"], "ref_ids": ["https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf", "23995855", "30867233"], "ref_urls": ["http://europepmc.org/abstract/MED/23995855", "http://europepmc.org/abstract/MED/30867233", "https://www.ema.europa.eu/en/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf"]}], "error": null}
{"id": "F3.2-000001", "family_id": "F3.2", "template_id": "f3_2_therapies_intersection_genes", "question": "What therapies target both TOP1 and ERBB2?", "cypher": "MATCH (t:Therapy)-[r1:TARGETS]->(g1:Gene)\nWHERE toLower(g1.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(g1.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nMATCH (t)-[r2:TARGETS]->(g2:Gene)\nWHERE toLower(g2.symbol) = toLower('ERBB2')\n   OR any(s IN coalesce(g2.synonyms, []) WHERE toLower(s) = toLower('ERBB2'))\nWITH t, g1, r1, g2, r2\nUNWIND [\n  {gene: g1, rel: r1},\n  {gene: g2, rel: r2}\n] AS pair\nRETURN\n  pair.gene.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  pair.rel.moa AS targets_moa,\n  coalesce(pair.rel.ref_sources, []) AS ref_sources,\n  coalesce(pair.rel.ref_ids, []) AS ref_ids,\n  coalesce(pair.rel.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "TOP1", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}, {"gene_symbol": "ERBB2", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "Receptor protein-tyrosine kinase erbB-2 binding agent", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}], "error": null}
{"id": "F3.2-000001-P1", "family_id": "F3.2", "template_id": "f3_2_therapies_intersection_genes", "question": "Which drugs target both TOP1 and ERBB2?", "cypher": "MATCH (t:Therapy)-[r1:TARGETS]->(g1:Gene)\nWHERE toLower(g1.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(g1.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nMATCH (t)-[r2:TARGETS]->(g2:Gene)\nWHERE toLower(g2.symbol) = toLower('ERBB2')\n   OR any(s IN coalesce(g2.synonyms, []) WHERE toLower(s) = toLower('ERBB2'))\nWITH t, g1, r1, g2, r2\nUNWIND [\n  {gene: g1, rel: r1},\n  {gene: g2, rel: r2}\n] AS pair\nRETURN\n  pair.gene.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  pair.rel.moa AS targets_moa,\n  coalesce(pair.rel.ref_sources, []) AS ref_sources,\n  coalesce(pair.rel.ref_ids, []) AS ref_ids,\n  coalesce(pair.rel.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "TOP1", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}, {"gene_symbol": "ERBB2", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "Receptor protein-tyrosine kinase erbB-2 binding agent", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}], "error": null}
{"id": "F3.2-000001-P2", "family_id": "F3.2", "template_id": "f3_2_therapies_intersection_genes", "question": "List therapies that hit TOP1 and ERBB2.", "cypher": "MATCH (t:Therapy)-[r1:TARGETS]->(g1:Gene)\nWHERE toLower(g1.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(g1.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nMATCH (t)-[r2:TARGETS]->(g2:Gene)\nWHERE toLower(g2.symbol) = toLower('ERBB2')\n   OR any(s IN coalesce(g2.synonyms, []) WHERE toLower(s) = toLower('ERBB2'))\nWITH t, g1, r1, g2, r2\nUNWIND [\n  {gene: g1, rel: r1},\n  {gene: g2, rel: r2}\n] AS pair\nRETURN\n  pair.gene.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  pair.rel.moa AS targets_moa,\n  coalesce(pair.rel.ref_sources, []) AS ref_sources,\n  coalesce(pair.rel.ref_ids, []) AS ref_ids,\n  coalesce(pair.rel.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "TOP1", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}, {"gene_symbol": "ERBB2", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "Receptor protein-tyrosine kinase erbB-2 binding agent", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}], "error": null}
{"id": "F3.2-000001-P3", "family_id": "F3.2", "template_id": "f3_2_therapies_intersection_genes", "question": "Show treatments targeting both TOP1 and ERBB2.", "cypher": "MATCH (t:Therapy)-[r1:TARGETS]->(g1:Gene)\nWHERE toLower(g1.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(g1.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nMATCH (t)-[r2:TARGETS]->(g2:Gene)\nWHERE toLower(g2.symbol) = toLower('ERBB2')\n   OR any(s IN coalesce(g2.synonyms, []) WHERE toLower(s) = toLower('ERBB2'))\nWITH t, g1, r1, g2, r2\nUNWIND [\n  {gene: g1, rel: r1},\n  {gene: g2, rel: r2}\n] AS pair\nRETURN\n  pair.gene.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  pair.rel.moa AS targets_moa,\n  coalesce(pair.rel.ref_sources, []) AS ref_sources,\n  coalesce(pair.rel.ref_ids, []) AS ref_ids,\n  coalesce(pair.rel.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "TOP1", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}, {"gene_symbol": "ERBB2", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "Receptor protein-tyrosine kinase erbB-2 binding agent", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}], "error": null}
{"id": "F3.3-000001", "family_id": "F3.3", "template_id": "f3_3_therapies_target_a_not_b", "question": "Which drugs target TOP1 but not ALK?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(gi:Gene)\nWHERE toLower(gi.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(gi.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nOPTIONAL MATCH (t)-[:TARGETS]->(gx:Gene)\nWHERE toLower(gx.symbol) = toLower('ALK')\n   OR any(s IN coalesce(gx.synonyms, []) WHERE toLower(s) = toLower('ALK'))\nWITH t, r, gi, gx\nWHERE gx IS NULL\nRETURN\n  gi.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "TOP1", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["DailyMed", "Other"], "ref_ids": ["setid=80f3b79c-a399-45b3-b755-8535457719af", "https://clincancerres.aacrjournals.org/content/clincanres/6/3/813.full.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f3b79c-a399-45b3-b755-8535457719af", "https://clincancerres.aacrjournals.org/content/clincanres/6/3/813.full.pdf"]}, {"gene_symbol": "TOP1", "therapy_name": "Datopotamab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["Other"], "ref_ids": ["https://mct.aacrjournals.org/content/18/12_Supplement/C026"], "ref_urls": ["https://mct.aacrjournals.org/content/18/12_Supplement/C026"]}, {"gene_symbol": "TOP1", "therapy_name": "Irinotecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=80f3b79c-a399-45b3-b755-8535457719af"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f3b79c-a399-45b3-b755-8535457719af"]}, {"gene_symbol": "TOP1", "therapy_name": "Sacituzumab Govitecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2020/761115s000lbl.pdf", "28503956", "28558150"], "ref_urls": ["http://europepmc.org/abstract/MED/28503956", "http://europepmc.org/abstract/MED/28558150", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf"]}, {"gene_symbol": "TOP1", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}], "error": null}
{"id": "F3.3-000001-P1", "family_id": "F3.3", "template_id": "f3_3_therapies_target_a_not_b", "question": "What therapies hit TOP1 but exclude ALK?", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(gi:Gene)\nWHERE toLower(gi.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(gi.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nOPTIONAL MATCH (t)-[:TARGETS]->(gx:Gene)\nWHERE toLower(gx.symbol) = toLower('ALK')\n   OR any(s IN coalesce(gx.synonyms, []) WHERE toLower(s) = toLower('ALK'))\nWITH t, r, gi, gx\nWHERE gx IS NULL\nRETURN\n  gi.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "TOP1", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["DailyMed", "Other"], "ref_ids": ["setid=80f3b79c-a399-45b3-b755-8535457719af", "https://clincancerres.aacrjournals.org/content/clincanres/6/3/813.full.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f3b79c-a399-45b3-b755-8535457719af", "https://clincancerres.aacrjournals.org/content/clincanres/6/3/813.full.pdf"]}, {"gene_symbol": "TOP1", "therapy_name": "Datopotamab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["Other"], "ref_ids": ["https://mct.aacrjournals.org/content/18/12_Supplement/C026"], "ref_urls": ["https://mct.aacrjournals.org/content/18/12_Supplement/C026"]}, {"gene_symbol": "TOP1", "therapy_name": "Irinotecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=80f3b79c-a399-45b3-b755-8535457719af"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f3b79c-a399-45b3-b755-8535457719af"]}, {"gene_symbol": "TOP1", "therapy_name": "Sacituzumab Govitecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2020/761115s000lbl.pdf", "28503956", "28558150"], "ref_urls": ["http://europepmc.org/abstract/MED/28503956", "http://europepmc.org/abstract/MED/28558150", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf"]}, {"gene_symbol": "TOP1", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}], "error": null}
{"id": "F3.3-000001-P2", "family_id": "F3.3", "template_id": "f3_3_therapies_target_a_not_b", "question": "List treatments targeting TOP1 and not ALK.", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(gi:Gene)\nWHERE toLower(gi.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(gi.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nOPTIONAL MATCH (t)-[:TARGETS]->(gx:Gene)\nWHERE toLower(gx.symbol) = toLower('ALK')\n   OR any(s IN coalesce(gx.synonyms, []) WHERE toLower(s) = toLower('ALK'))\nWITH t, r, gi, gx\nWHERE gx IS NULL\nRETURN\n  gi.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "TOP1", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["DailyMed", "Other"], "ref_ids": ["setid=80f3b79c-a399-45b3-b755-8535457719af", "https://clincancerres.aacrjournals.org/content/clincanres/6/3/813.full.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f3b79c-a399-45b3-b755-8535457719af", "https://clincancerres.aacrjournals.org/content/clincanres/6/3/813.full.pdf"]}, {"gene_symbol": "TOP1", "therapy_name": "Datopotamab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["Other"], "ref_ids": ["https://mct.aacrjournals.org/content/18/12_Supplement/C026"], "ref_urls": ["https://mct.aacrjournals.org/content/18/12_Supplement/C026"]}, {"gene_symbol": "TOP1", "therapy_name": "Irinotecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=80f3b79c-a399-45b3-b755-8535457719af"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f3b79c-a399-45b3-b755-8535457719af"]}, {"gene_symbol": "TOP1", "therapy_name": "Sacituzumab Govitecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2020/761115s000lbl.pdf", "28503956", "28558150"], "ref_urls": ["http://europepmc.org/abstract/MED/28503956", "http://europepmc.org/abstract/MED/28558150", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf"]}, {"gene_symbol": "TOP1", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}], "error": null}
{"id": "F3.3-000001-P3", "family_id": "F3.3", "template_id": "f3_3_therapies_target_a_not_b", "question": "Show therapies for TOP1 but not for ALK.", "cypher": "MATCH (t:Therapy)-[r:TARGETS]->(gi:Gene)\nWHERE toLower(gi.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(gi.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nOPTIONAL MATCH (t)-[:TARGETS]->(gx:Gene)\nWHERE toLower(gx.symbol) = toLower('ALK')\n   OR any(s IN coalesce(gx.synonyms, []) WHERE toLower(s) = toLower('ALK'))\nWITH t, r, gi, gx\nWHERE gx IS NULL\nRETURN\n  gi.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "TOP1", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["DailyMed", "Other"], "ref_ids": ["setid=80f3b79c-a399-45b3-b755-8535457719af", "https://clincancerres.aacrjournals.org/content/clincanres/6/3/813.full.pdf"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f3b79c-a399-45b3-b755-8535457719af", "https://clincancerres.aacrjournals.org/content/clincanres/6/3/813.full.pdf"]}, {"gene_symbol": "TOP1", "therapy_name": "Datopotamab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["Other"], "ref_ids": ["https://mct.aacrjournals.org/content/18/12_Supplement/C026"], "ref_urls": ["https://mct.aacrjournals.org/content/18/12_Supplement/C026"]}, {"gene_symbol": "TOP1", "therapy_name": "Irinotecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=80f3b79c-a399-45b3-b755-8535457719af"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f3b79c-a399-45b3-b755-8535457719af"]}, {"gene_symbol": "TOP1", "therapy_name": "Sacituzumab Govitecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2020/761115s000lbl.pdf", "28503956", "28558150"], "ref_urls": ["http://europepmc.org/abstract/MED/28503956", "http://europepmc.org/abstract/MED/28558150", "http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf"]}, {"gene_symbol": "TOP1", "therapy_name": "Trastuzumab Deruxtecan", "targets_moa": "DNA topoisomerase I inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2019/761139s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf"]}], "error": null}
{"id": "F4.1-000001", "family_id": "F4.1", "template_id": "f4_1_target_validation_gene_disease", "question": "Which therapies target TOP1 and also have biomarker evidence in Colon Carcinoma?", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nMATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'colon' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(bg:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE bg.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "MSH3 K383fs", "gene_symbol": "MSH3", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "effect": "sensitivity", "disease_name": "Colon Carcinoma", "pmids": ["23724141"]}], "error": null}
{"id": "F4.1-000001-P1", "family_id": "F4.1", "template_id": "f4_1_target_validation_gene_disease", "question": "What drugs targeting TOP1 have biomarker evidence in Colon Carcinoma?", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nMATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'colon' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(bg:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE bg.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "MSH3 K383fs", "gene_symbol": "MSH3", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "effect": "sensitivity", "disease_name": "Colon Carcinoma", "pmids": ["23724141"]}], "error": null}
{"id": "F4.1-000001-P2", "family_id": "F4.1", "template_id": "f4_1_target_validation_gene_disease", "question": "List therapies that target TOP1 with evidence in Colon Carcinoma.", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nMATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'colon' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(bg:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE bg.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "MSH3 K383fs", "gene_symbol": "MSH3", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "effect": "sensitivity", "disease_name": "Colon Carcinoma", "pmids": ["23724141"]}], "error": null}
{"id": "F4.1-000001-P3", "family_id": "F4.1", "template_id": "f4_1_target_validation_gene_disease", "question": "Show treatments hitting TOP1 that have biomarker evidence in Colon Carcinoma.", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nMATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'colon' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(bg:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE bg.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "MSH3 K383fs", "gene_symbol": "MSH3", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "effect": "sensitivity", "disease_name": "Colon Carcinoma", "pmids": ["23724141"]}], "error": null}
{"id": "F4.2-000001", "family_id": "F4.2", "template_id": "f4_2_alternative_therapies_from_resistance_genes", "question": "For resistance to MEK Inhibitor RO4987655 in Lung Non-small Cell Carcinoma, which therapies target the resistance biomarkers?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t1:Therapy)\nWHERE (\n  toLower(t1.name) = toLower('MEK Inhibitor RO4987655')\n  OR any(s IN coalesce(t1.synonyms, []) WHERE toLower(s) = toLower('MEK Inhibitor RO4987655'))\n  OR toLower(t1.name) CONTAINS toLower('MEK Inhibitor RO4987655')\n)\n  AND toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol\nWHERE gene_symbol IS NOT NULL\nMATCH (t2:Therapy)-[r:TARGETS]->(tg:Gene)\nWHERE (\n  toLower(tg.symbol) = toLower(gene_symbol)\n  OR any(s IN coalesce(tg.synonyms, []) WHERE toLower(s) = toLower(gene_symbol))\n)\n  AND toLower(t2.name) <> toLower('MEK Inhibitor RO4987655')\nRETURN\n  gene_symbol,\n  t2.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "KRAS", "therapy_name": "Adagrasib", "targets_moa": "GTPase KRas inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["31658955"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/31658955/"]}, {"gene_symbol": "KRAS", "therapy_name": "Salirasib", "targets_moa": "RAS inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["22547163"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/22547163/"]}, {"gene_symbol": "KRAS", "therapy_name": "Sotorasib", "targets_moa": "GTPase KRas inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["31189530", "31666701", "31820981", "32568546"], "ref_urls": ["http://europepmc.org/abstract/MED/31189530", "http://europepmc.org/abstract/MED/31666701", "http://europepmc.org/abstract/MED/31820981", "http://europepmc.org/abstract/MED/32568546"]}], "error": null}
{"id": "F4.2-000001-P1", "family_id": "F4.2", "template_id": "f4_2_alternative_therapies_from_resistance_genes", "question": "In Lung Non-small Cell Carcinoma, what therapies target genes causing resistance to MEK Inhibitor RO4987655?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t1:Therapy)\nWHERE (\n  toLower(t1.name) = toLower('MEK Inhibitor RO4987655')\n  OR any(s IN coalesce(t1.synonyms, []) WHERE toLower(s) = toLower('MEK Inhibitor RO4987655'))\n  OR toLower(t1.name) CONTAINS toLower('MEK Inhibitor RO4987655')\n)\n  AND toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol\nWHERE gene_symbol IS NOT NULL\nMATCH (t2:Therapy)-[r:TARGETS]->(tg:Gene)\nWHERE (\n  toLower(tg.symbol) = toLower(gene_symbol)\n  OR any(s IN coalesce(tg.synonyms, []) WHERE toLower(s) = toLower(gene_symbol))\n)\n  AND toLower(t2.name) <> toLower('MEK Inhibitor RO4987655')\nRETURN\n  gene_symbol,\n  t2.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "KRAS", "therapy_name": "Adagrasib", "targets_moa": "GTPase KRas inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["31658955"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/31658955/"]}, {"gene_symbol": "KRAS", "therapy_name": "Salirasib", "targets_moa": "RAS inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["22547163"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/22547163/"]}, {"gene_symbol": "KRAS", "therapy_name": "Sotorasib", "targets_moa": "GTPase KRas inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["31189530", "31666701", "31820981", "32568546"], "ref_urls": ["http://europepmc.org/abstract/MED/31189530", "http://europepmc.org/abstract/MED/31666701", "http://europepmc.org/abstract/MED/31820981", "http://europepmc.org/abstract/MED/32568546"]}], "error": null}
{"id": "F4.2-000001-P2", "family_id": "F4.2", "template_id": "f4_2_alternative_therapies_from_resistance_genes", "question": "Which drugs target biomarkers of resistance to MEK Inhibitor RO4987655 in Lung Non-small Cell Carcinoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t1:Therapy)\nWHERE (\n  toLower(t1.name) = toLower('MEK Inhibitor RO4987655')\n  OR any(s IN coalesce(t1.synonyms, []) WHERE toLower(s) = toLower('MEK Inhibitor RO4987655'))\n  OR toLower(t1.name) CONTAINS toLower('MEK Inhibitor RO4987655')\n)\n  AND toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol\nWHERE gene_symbol IS NOT NULL\nMATCH (t2:Therapy)-[r:TARGETS]->(tg:Gene)\nWHERE (\n  toLower(tg.symbol) = toLower(gene_symbol)\n  OR any(s IN coalesce(tg.synonyms, []) WHERE toLower(s) = toLower(gene_symbol))\n)\n  AND toLower(t2.name) <> toLower('MEK Inhibitor RO4987655')\nRETURN\n  gene_symbol,\n  t2.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "KRAS", "therapy_name": "Adagrasib", "targets_moa": "GTPase KRas inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["31658955"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/31658955/"]}, {"gene_symbol": "KRAS", "therapy_name": "Salirasib", "targets_moa": "RAS inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["22547163"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/22547163/"]}, {"gene_symbol": "KRAS", "therapy_name": "Sotorasib", "targets_moa": "GTPase KRas inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["31189530", "31666701", "31820981", "32568546"], "ref_urls": ["http://europepmc.org/abstract/MED/31189530", "http://europepmc.org/abstract/MED/31666701", "http://europepmc.org/abstract/MED/31820981", "http://europepmc.org/abstract/MED/32568546"]}], "error": null}
{"id": "F4.2-000001-P3", "family_id": "F4.2", "template_id": "f4_2_alternative_therapies_from_resistance_genes", "question": "Find therapies that target resistance genes for MEK Inhibitor RO4987655 in Lung Non-small Cell Carcinoma.", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t1:Therapy)\nWHERE (\n  toLower(t1.name) = toLower('MEK Inhibitor RO4987655')\n  OR any(s IN coalesce(t1.synonyms, []) WHERE toLower(s) = toLower('MEK Inhibitor RO4987655'))\n  OR toLower(t1.name) CONTAINS toLower('MEK Inhibitor RO4987655')\n)\n  AND toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol\nWHERE gene_symbol IS NOT NULL\nMATCH (t2:Therapy)-[r:TARGETS]->(tg:Gene)\nWHERE (\n  toLower(tg.symbol) = toLower(gene_symbol)\n  OR any(s IN coalesce(tg.synonyms, []) WHERE toLower(s) = toLower(gene_symbol))\n)\n  AND toLower(t2.name) <> toLower('MEK Inhibitor RO4987655')\nRETURN\n  gene_symbol,\n  t2.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "KRAS", "therapy_name": "Adagrasib", "targets_moa": "GTPase KRas inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["31658955"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/31658955/"]}, {"gene_symbol": "KRAS", "therapy_name": "Salirasib", "targets_moa": "RAS inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["22547163"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/22547163/"]}, {"gene_symbol": "KRAS", "therapy_name": "Sotorasib", "targets_moa": "GTPase KRas inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["31189530", "31666701", "31820981", "32568546"], "ref_urls": ["http://europepmc.org/abstract/MED/31189530", "http://europepmc.org/abstract/MED/31666701", "http://europepmc.org/abstract/MED/31820981", "http://europepmc.org/abstract/MED/32568546"]}], "error": null}
{"id": "F5.1-000001", "family_id": "F5.1", "template_id": "f5_1_biomarkers_in_disease", "question": "In Spindle Cell Rhabdomyosarcoma, which biomarkers have evidence?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'spindle' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'rhabdomyosarcoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "FUS FUS::TFCP2 Fusion AND ALK Exon 2-18 Deletion", "gene_symbol": "FUS", "therapy_name": "Alectinib", "effect": "sensitivity", "disease_name": "Spindle Cell Rhabdomyosarcoma", "pmids": ["39302072"]}], "error": null}
{"id": "F5.1-000001-P1", "family_id": "F5.1", "template_id": "f5_1_biomarkers_in_disease", "question": "Which biomarkers show evidence in Spindle Cell Rhabdomyosarcoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'spindle' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'rhabdomyosarcoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "FUS FUS::TFCP2 Fusion AND ALK Exon 2-18 Deletion", "gene_symbol": "FUS", "therapy_name": "Alectinib", "effect": "sensitivity", "disease_name": "Spindle Cell Rhabdomyosarcoma", "pmids": ["39302072"]}], "error": null}
{"id": "F5.1-000001-P2", "family_id": "F5.1", "template_id": "f5_1_biomarkers_in_disease", "question": "List biomarkers with AFFECTS evidence in Spindle Cell Rhabdomyosarcoma.", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'spindle' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'rhabdomyosarcoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "FUS FUS::TFCP2 Fusion AND ALK Exon 2-18 Deletion", "gene_symbol": "FUS", "therapy_name": "Alectinib", "effect": "sensitivity", "disease_name": "Spindle Cell Rhabdomyosarcoma", "pmids": ["39302072"]}], "error": null}
{"id": "F5.1-000001-P3", "family_id": "F5.1", "template_id": "f5_1_biomarkers_in_disease", "question": "What biomarkers have therapy response evidence in Spindle Cell Rhabdomyosarcoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'spindle' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'rhabdomyosarcoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "FUS FUS::TFCP2 Fusion AND ALK Exon 2-18 Deletion", "gene_symbol": "FUS", "therapy_name": "Alectinib", "effect": "sensitivity", "disease_name": "Spindle Cell Rhabdomyosarcoma", "pmids": ["39302072"]}], "error": null}
{"id": "F5.2-000001", "family_id": "F5.2", "template_id": "f5_2_therapies_with_biomarker_evidence_in_disease", "question": "List therapies with variant-level biomarkers in Anaplastic Ependymoma.", "cypher": "MATCH (v:Variant)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'anaplastic' AND\n    toLower(rel.disease_name) CONTAINS 'ependymoma'\n  )\nOPTIONAL MATCH (v)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "KANK1 KANK1::NTRK2 Fusion", "gene_symbol": "KANK1", "therapy_name": "Larotrectinib", "effect": "sensitivity", "disease_name": "Anaplastic Ependymoma", "pmids": ["34651095"]}], "error": null}
{"id": "F5.2-000001-P1", "family_id": "F5.2", "template_id": "f5_2_therapies_with_biomarker_evidence_in_disease", "question": "Which therapies have variant biomarkers in Anaplastic Ependymoma?", "cypher": "MATCH (v:Variant)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'anaplastic' AND\n    toLower(rel.disease_name) CONTAINS 'ependymoma'\n  )\nOPTIONAL MATCH (v)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "KANK1 KANK1::NTRK2 Fusion", "gene_symbol": "KANK1", "therapy_name": "Larotrectinib", "effect": "sensitivity", "disease_name": "Anaplastic Ependymoma", "pmids": ["34651095"]}], "error": null}
{"id": "F5.2-000001-P2", "family_id": "F5.2", "template_id": "f5_2_therapies_with_biomarker_evidence_in_disease", "question": "Show drugs with variant-based evidence in Anaplastic Ependymoma.", "cypher": "MATCH (v:Variant)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'anaplastic' AND\n    toLower(rel.disease_name) CONTAINS 'ependymoma'\n  )\nOPTIONAL MATCH (v)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "KANK1 KANK1::NTRK2 Fusion", "gene_symbol": "KANK1", "therapy_name": "Larotrectinib", "effect": "sensitivity", "disease_name": "Anaplastic Ependymoma", "pmids": ["34651095"]}], "error": null}
{"id": "F5.2-000001-P3", "family_id": "F5.2", "template_id": "f5_2_therapies_with_biomarker_evidence_in_disease", "question": "List treatments supported by variant evidence in Anaplastic Ependymoma.", "cypher": "MATCH (v:Variant)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'anaplastic' AND\n    toLower(rel.disease_name) CONTAINS 'ependymoma'\n  )\nOPTIONAL MATCH (v)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "KANK1 KANK1::NTRK2 Fusion", "gene_symbol": "KANK1", "therapy_name": "Larotrectinib", "effect": "sensitivity", "disease_name": "Anaplastic Ependymoma", "pmids": ["34651095"]}], "error": null}
{"id": "F6.1-000001", "family_id": "F6.1", "template_id": "f6_1_resistance_genes_for_union_therapies_in_disease", "question": "Which genes predict resistance to JNJ38877605 or WZ4002 in Lung Non-small Cell Carcinoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('JNJ38877605')\n  OR toLower(t.name) = toLower('WZ4002')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('JNJ38877605'))\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('WZ4002'))\n  OR toLower(t.name) CONTAINS toLower('JNJ38877605')\n  OR toLower(t.name) CONTAINS toLower('WZ4002')\n)\nAND toLower(rel.effect) = 'resistance'\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'resistance' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "JNJ38877605", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["20841479"]}, {"variant_name": null, "gene_symbol": "MAPK1", "therapy_name": "WZ4002", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["22961667"]}], "error": null}
{"id": "F6.1-000001-P1", "family_id": "F6.1", "template_id": "f6_1_resistance_genes_for_union_therapies_in_disease", "question": "In Lung Non-small Cell Carcinoma, which genes confer resistance to JNJ38877605 or WZ4002?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('JNJ38877605')\n  OR toLower(t.name) = toLower('WZ4002')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('JNJ38877605'))\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('WZ4002'))\n  OR toLower(t.name) CONTAINS toLower('JNJ38877605')\n  OR toLower(t.name) CONTAINS toLower('WZ4002')\n)\nAND toLower(rel.effect) = 'resistance'\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'resistance' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "JNJ38877605", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["20841479"]}, {"variant_name": null, "gene_symbol": "MAPK1", "therapy_name": "WZ4002", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["22961667"]}], "error": null}
{"id": "F6.1-000001-P2", "family_id": "F6.1", "template_id": "f6_1_resistance_genes_for_union_therapies_in_disease", "question": "List resistance genes for JNJ38877605 or WZ4002 in Lung Non-small Cell Carcinoma.", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('JNJ38877605')\n  OR toLower(t.name) = toLower('WZ4002')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('JNJ38877605'))\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('WZ4002'))\n  OR toLower(t.name) CONTAINS toLower('JNJ38877605')\n  OR toLower(t.name) CONTAINS toLower('WZ4002')\n)\nAND toLower(rel.effect) = 'resistance'\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'resistance' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "JNJ38877605", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["20841479"]}, {"variant_name": null, "gene_symbol": "MAPK1", "therapy_name": "WZ4002", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["22961667"]}], "error": null}
{"id": "F6.1-000001-P3", "family_id": "F6.1", "template_id": "f6_1_resistance_genes_for_union_therapies_in_disease", "question": "What genes are resistance biomarkers for JNJ38877605 or WZ4002 in Lung Non-small Cell Carcinoma?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t:Therapy)\nWHERE (\n  toLower(t.name) = toLower('JNJ38877605')\n  OR toLower(t.name) = toLower('WZ4002')\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('JNJ38877605'))\n  OR any(s IN coalesce(t.synonyms, []) WHERE toLower(s) = toLower('WZ4002'))\n  OR toLower(t.name) CONTAINS toLower('JNJ38877605')\n  OR toLower(t.name) CONTAINS toLower('WZ4002')\n)\nAND toLower(rel.effect) = 'resistance'\nAND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nWHERE gene_symbol IS NOT NULL\nUNWIND pmids AS p\nWITH gene_symbol, therapy_name, disease_name, collect(DISTINCT p) AS pmids\nRETURN\n  NULL AS variant_name,\n  gene_symbol,\n  therapy_name,\n  'resistance' AS effect,\n  disease_name,\n  pmids\nLIMIT 100\n", "result": [{"variant_name": null, "gene_symbol": "KRAS", "therapy_name": "JNJ38877605", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["20841479"]}, {"variant_name": null, "gene_symbol": "MAPK1", "therapy_name": "WZ4002", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["22961667"]}], "error": null}
{"id": "F6.2-000001", "family_id": "F6.2", "template_id": "f6_2_therapies_target_gene_not_other_with_disease_evidence", "question": "What therapies target TOP1 but NOT ALK, and have biomarker evidence in Colon Carcinoma?", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(gi:Gene)\nWHERE toLower(gi.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(gi.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nOPTIONAL MATCH (t)-[:TARGETS]->(gx:Gene)\nWHERE toLower(gx.symbol) = toLower('ALK')\n   OR any(s IN coalesce(gx.synonyms, []) WHERE toLower(s) = toLower('ALK'))\nWITH t, gi, gx\nWHERE gx IS NULL\nMATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'colon' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "MSH3 K383fs", "gene_symbol": "MSH3", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "effect": "sensitivity", "disease_name": "Colon Carcinoma", "pmids": ["23724141"]}], "error": null}
{"id": "F6.2-000001-P1", "family_id": "F6.2", "template_id": "f6_2_therapies_target_gene_not_other_with_disease_evidence", "question": "Which drugs hit TOP1 but not ALK with evidence in Colon Carcinoma?", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(gi:Gene)\nWHERE toLower(gi.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(gi.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nOPTIONAL MATCH (t)-[:TARGETS]->(gx:Gene)\nWHERE toLower(gx.symbol) = toLower('ALK')\n   OR any(s IN coalesce(gx.synonyms, []) WHERE toLower(s) = toLower('ALK'))\nWITH t, gi, gx\nWHERE gx IS NULL\nMATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'colon' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "MSH3 K383fs", "gene_symbol": "MSH3", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "effect": "sensitivity", "disease_name": "Colon Carcinoma", "pmids": ["23724141"]}], "error": null}
{"id": "F6.2-000001-P2", "family_id": "F6.2", "template_id": "f6_2_therapies_target_gene_not_other_with_disease_evidence", "question": "List therapies targeting TOP1 (not ALK) with evidence in Colon Carcinoma.", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(gi:Gene)\nWHERE toLower(gi.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(gi.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nOPTIONAL MATCH (t)-[:TARGETS]->(gx:Gene)\nWHERE toLower(gx.symbol) = toLower('ALK')\n   OR any(s IN coalesce(gx.synonyms, []) WHERE toLower(s) = toLower('ALK'))\nWITH t, gi, gx\nWHERE gx IS NULL\nMATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'colon' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "MSH3 K383fs", "gene_symbol": "MSH3", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "effect": "sensitivity", "disease_name": "Colon Carcinoma", "pmids": ["23724141"]}], "error": null}
{"id": "F6.2-000001-P3", "family_id": "F6.2", "template_id": "f6_2_therapies_target_gene_not_other_with_disease_evidence", "question": "Show treatments for TOP1 excluding ALK that have biomarker evidence in Colon Carcinoma.", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(gi:Gene)\nWHERE toLower(gi.symbol) = toLower('TOP1')\n   OR any(s IN coalesce(gi.synonyms, []) WHERE toLower(s) = toLower('TOP1'))\nOPTIONAL MATCH (t)-[:TARGETS]->(gx:Gene)\nWHERE toLower(gx.symbol) = toLower('ALK')\n   OR any(s IN coalesce(gx.synonyms, []) WHERE toLower(s) = toLower('ALK'))\nWITH t, gi, gx\nWHERE gx IS NULL\nMATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE (\n    toLower(rel.disease_name) CONTAINS 'colon' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nRETURN\n  CASE WHEN b:Variant THEN b.name ELSE NULL END AS variant_name,\n  CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol,\n  t.name AS therapy_name,\n  rel.effect AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "MSH3 K383fs", "gene_symbol": "MSH3", "therapy_name": "7-Ethyl-10-Hydroxycamptothecin", "effect": "sensitivity", "disease_name": "Colon Carcinoma", "pmids": ["23724141"]}], "error": null}
{"id": "F6.3-000001", "family_id": "F6.3", "template_id": "f6_3_therapies_target_gene_with_variant_resistance_in_disease", "question": "Find therapies that target EGFR for variants that cause resistance in Lung Non-small Cell Carcinoma.", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('EGFR')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('EGFR'))\nMATCH (v:Variant)-[:VARIANT_OF]->(g)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'resistance' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "EGFR Mutation", "gene_symbol": "EGFR", "therapy_name": "Afatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25948633"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Afatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24035188"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21430269"]}, {"variant_name": "EGFR A767_V769dupASV", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21132006"]}, {"variant_name": "EGFR A859T", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17877814"]}, {"variant_name": "EGFR D761Y", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17085664"]}, {"variant_name": "EGFR D770_N771insNPG", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR D770_N771insSVD", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160", "17877814"]}, {"variant_name": "EGFR H773_V774insH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR M766_A767insAI", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR N771delinsGY", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21132006"]}, {"variant_name": "EGFR N826S", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19147750"]}, {"variant_name": "EGFR P772_H773insH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR P772_H773insYNP", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR P848L", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17877814"]}, {"variant_name": "EGFR S768N", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19786660", "21132006"]}, {"variant_name": "EGFR S784F", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21841502"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25668228", "27304188", "15737014", "21132006"]}, {"variant_name": "EGFR V769_D770insASV", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR Y764_V765insHH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR D761Y", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17085664"]}, {"variant_name": "EGFR Mutation", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25948633"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["15728811", "17020982", "15737014"]}, {"variant_name": "EGFR Wildtype", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19692680"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Lapatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["18408761"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Naquotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["29386539"]}, {"variant_name": "EGFR Amplification", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28202511"]}, {"variant_name": "EGFR C797S", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25939061"]}, {"variant_name": "EGFR M766Q", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["31254668"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["29386539"]}, {"variant_name": "EGFR Amplification", "gene_symbol": "EGFR", "therapy_name": "Rociletinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28202511"]}], "error": null}
{"id": "F6.3-000001-P1", "family_id": "F6.3", "template_id": "f6_3_therapies_target_gene_with_variant_resistance_in_disease", "question": "Which therapies targeting EGFR have variant-level resistance in Lung Non-small Cell Carcinoma?", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('EGFR')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('EGFR'))\nMATCH (v:Variant)-[:VARIANT_OF]->(g)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'resistance' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "EGFR Mutation", "gene_symbol": "EGFR", "therapy_name": "Afatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25948633"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Afatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24035188"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21430269"]}, {"variant_name": "EGFR A767_V769dupASV", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21132006"]}, {"variant_name": "EGFR A859T", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17877814"]}, {"variant_name": "EGFR D761Y", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17085664"]}, {"variant_name": "EGFR D770_N771insNPG", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR D770_N771insSVD", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160", "17877814"]}, {"variant_name": "EGFR H773_V774insH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR M766_A767insAI", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR N771delinsGY", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21132006"]}, {"variant_name": "EGFR N826S", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19147750"]}, {"variant_name": "EGFR P772_H773insH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR P772_H773insYNP", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR P848L", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17877814"]}, {"variant_name": "EGFR S768N", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19786660", "21132006"]}, {"variant_name": "EGFR S784F", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21841502"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25668228", "27304188", "15737014", "21132006"]}, {"variant_name": "EGFR V769_D770insASV", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR Y764_V765insHH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR D761Y", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17085664"]}, {"variant_name": "EGFR Mutation", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25948633"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["15728811", "17020982", "15737014"]}, {"variant_name": "EGFR Wildtype", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19692680"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Lapatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["18408761"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Naquotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["29386539"]}, {"variant_name": "EGFR Amplification", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28202511"]}, {"variant_name": "EGFR C797S", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25939061"]}, {"variant_name": "EGFR M766Q", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["31254668"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["29386539"]}, {"variant_name": "EGFR Amplification", "gene_symbol": "EGFR", "therapy_name": "Rociletinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28202511"]}], "error": null}
{"id": "F6.3-000001-P2", "family_id": "F6.3", "template_id": "f6_3_therapies_target_gene_with_variant_resistance_in_disease", "question": "List drugs targeting EGFR with resistant variants in Lung Non-small Cell Carcinoma.", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('EGFR')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('EGFR'))\nMATCH (v:Variant)-[:VARIANT_OF]->(g)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'resistance' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "EGFR Mutation", "gene_symbol": "EGFR", "therapy_name": "Afatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25948633"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Afatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24035188"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21430269"]}, {"variant_name": "EGFR A767_V769dupASV", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21132006"]}, {"variant_name": "EGFR A859T", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17877814"]}, {"variant_name": "EGFR D761Y", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17085664"]}, {"variant_name": "EGFR D770_N771insNPG", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR D770_N771insSVD", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160", "17877814"]}, {"variant_name": "EGFR H773_V774insH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR M766_A767insAI", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR N771delinsGY", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21132006"]}, {"variant_name": "EGFR N826S", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19147750"]}, {"variant_name": "EGFR P772_H773insH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR P772_H773insYNP", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR P848L", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17877814"]}, {"variant_name": "EGFR S768N", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19786660", "21132006"]}, {"variant_name": "EGFR S784F", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21841502"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25668228", "27304188", "15737014", "21132006"]}, {"variant_name": "EGFR V769_D770insASV", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR Y764_V765insHH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR D761Y", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17085664"]}, {"variant_name": "EGFR Mutation", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25948633"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["15728811", "17020982", "15737014"]}, {"variant_name": "EGFR Wildtype", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19692680"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Lapatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["18408761"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Naquotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["29386539"]}, {"variant_name": "EGFR Amplification", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28202511"]}, {"variant_name": "EGFR C797S", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25939061"]}, {"variant_name": "EGFR M766Q", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["31254668"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["29386539"]}, {"variant_name": "EGFR Amplification", "gene_symbol": "EGFR", "therapy_name": "Rociletinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28202511"]}], "error": null}
{"id": "F6.3-000001-P3", "family_id": "F6.3", "template_id": "f6_3_therapies_target_gene_with_variant_resistance_in_disease", "question": "Show therapies for EGFR where variants cause resistance in Lung Non-small Cell Carcinoma.", "cypher": "MATCH (t:Therapy)-[:TARGETS]->(g:Gene)\nWHERE toLower(g.symbol) = toLower('EGFR')\n   OR any(s IN coalesce(g.synonyms, []) WHERE toLower(s) = toLower('EGFR'))\nMATCH (v:Variant)-[:VARIANT_OF]->(g)\nMATCH (v)-[rel:AFFECTS_RESPONSE_TO]->(t)\nWHERE toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung' AND\n    toLower(rel.disease_name) CONTAINS 'non-small' AND\n    toLower(rel.disease_name) CONTAINS 'cell' AND\n    toLower(rel.disease_name) CONTAINS 'carcinoma'\n  )\nRETURN\n  v.name AS variant_name,\n  g.symbol AS gene_symbol,\n  t.name AS therapy_name,\n  'resistance' AS effect,\n  rel.disease_name AS disease_name,\n  coalesce(rel.pmids, []) AS pmids\nLIMIT 100\n", "result": [{"variant_name": "EGFR Mutation", "gene_symbol": "EGFR", "therapy_name": "Afatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25948633"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Afatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24035188"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21430269"]}, {"variant_name": "EGFR A767_V769dupASV", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21132006"]}, {"variant_name": "EGFR A859T", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17877814"]}, {"variant_name": "EGFR D761Y", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17085664"]}, {"variant_name": "EGFR D770_N771insNPG", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR D770_N771insSVD", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160", "17877814"]}, {"variant_name": "EGFR H773_V774insH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR M766_A767insAI", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR N771delinsGY", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21132006"]}, {"variant_name": "EGFR N826S", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19147750"]}, {"variant_name": "EGFR P772_H773insH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR P772_H773insYNP", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR P848L", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17877814"]}, {"variant_name": "EGFR S768N", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19786660", "21132006"]}, {"variant_name": "EGFR S784F", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["21841502"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25668228", "27304188", "15737014", "21132006"]}, {"variant_name": "EGFR V769_D770insASV", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR Y764_V765insHH", "gene_symbol": "EGFR", "therapy_name": "Erlotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["24353160"]}, {"variant_name": "EGFR D761Y", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["17085664"]}, {"variant_name": "EGFR Mutation", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25948633"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["15728811", "17020982", "15737014"]}, {"variant_name": "EGFR Wildtype", "gene_symbol": "EGFR", "therapy_name": "Gefitinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["19692680"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Lapatinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["18408761"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Naquotinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["29386539"]}, {"variant_name": "EGFR Amplification", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28202511"]}, {"variant_name": "EGFR C797S", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["25939061"]}, {"variant_name": "EGFR M766Q", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["31254668"]}, {"variant_name": "EGFR T790M", "gene_symbol": "EGFR", "therapy_name": "Osimertinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["29386539"]}, {"variant_name": "EGFR Amplification", "gene_symbol": "EGFR", "therapy_name": "Rociletinib", "effect": "resistance", "disease_name": "Lung Non-small Cell Carcinoma", "pmids": ["28202511"]}], "error": null}
{"id": "F6.4-000001", "family_id": "F6.4", "template_id": "f6_4_alternative_therapies_for_resistance_in_disease", "question": "For resistance to Erlotinib in Lung Cancer, which therapies target the resistance biomarkers?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t1:Therapy)\nWHERE (\n  toLower(t1.name) = toLower('Erlotinib')\n  OR any(s IN coalesce(t1.synonyms, []) WHERE toLower(s) = toLower('Erlotinib'))\n  OR toLower(t1.name) CONTAINS toLower('Erlotinib')\n)\n  AND toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol\nWHERE gene_symbol IS NOT NULL\nMATCH (t2:Therapy)-[r:TARGETS]->(tg:Gene)\nWHERE (\n  toLower(tg.symbol) = toLower(gene_symbol)\n  OR any(s IN coalesce(tg.synonyms, []) WHERE toLower(s) = toLower(gene_symbol))\n)\n  AND toLower(t2.name) <> toLower('Erlotinib')\nRETURN\n  gene_symbol,\n  t2.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "therapy_name": "Agerafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "BRAF Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}, {"gene_symbol": "BRAF", "therapy_name": "Belvarafenib", "targets_moa": "RAF serine/threonine protein kinase inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570", "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3000"], "ref_urls": ["https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570", "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3000"]}, {"gene_symbol": "BRAF", "therapy_name": "Dabrafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=803beaaa-33f9-48cc-9a95-c2e887e095b4#nlm34090-1"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4#nlm34090-1"]}, {"gene_symbol": "BRAF", "therapy_name": "Encorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}, {"gene_symbol": "BRAF", "therapy_name": "Pan-RAF Inhibitor LY3009120", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["25965804"], "ref_urls": ["http://europepmc.org/abstract/MED/25965804"]}, {"gene_symbol": "BRAF", "therapy_name": "Regorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Regorafenib Anhydrous", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Sorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/021923s012lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Sorafenib Tosylate", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/021923s012lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "TRK Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Tovorafenib", "targets_moa": "RAF serine/threonine protein kinase inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710688", "http://www.sunesis.com/products-in-development/product/MLN2480.php", "5653214"], "ref_urls": ["http://europepmc.org/abstract/MED/5653214", "http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710688", "http://www.sunesis.com/products-in-development/product/MLN2480.php"]}, {"gene_symbol": "BRAF", "therapy_name": "Vemurafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/202429s000lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}], "error": null}
{"id": "F6.4-000001-P1", "family_id": "F6.4", "template_id": "f6_4_alternative_therapies_for_resistance_in_disease", "question": "In Lung Cancer, what therapies target genes linked to resistance to Erlotinib?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t1:Therapy)\nWHERE (\n  toLower(t1.name) = toLower('Erlotinib')\n  OR any(s IN coalesce(t1.synonyms, []) WHERE toLower(s) = toLower('Erlotinib'))\n  OR toLower(t1.name) CONTAINS toLower('Erlotinib')\n)\n  AND toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol\nWHERE gene_symbol IS NOT NULL\nMATCH (t2:Therapy)-[r:TARGETS]->(tg:Gene)\nWHERE (\n  toLower(tg.symbol) = toLower(gene_symbol)\n  OR any(s IN coalesce(tg.synonyms, []) WHERE toLower(s) = toLower(gene_symbol))\n)\n  AND toLower(t2.name) <> toLower('Erlotinib')\nRETURN\n  gene_symbol,\n  t2.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "therapy_name": "Agerafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "BRAF Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}, {"gene_symbol": "BRAF", "therapy_name": "Belvarafenib", "targets_moa": "RAF serine/threonine protein kinase inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570", "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3000"], "ref_urls": ["https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570", "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3000"]}, {"gene_symbol": "BRAF", "therapy_name": "Dabrafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=803beaaa-33f9-48cc-9a95-c2e887e095b4#nlm34090-1"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4#nlm34090-1"]}, {"gene_symbol": "BRAF", "therapy_name": "Encorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}, {"gene_symbol": "BRAF", "therapy_name": "Pan-RAF Inhibitor LY3009120", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["25965804"], "ref_urls": ["http://europepmc.org/abstract/MED/25965804"]}, {"gene_symbol": "BRAF", "therapy_name": "Regorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Regorafenib Anhydrous", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Sorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/021923s012lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Sorafenib Tosylate", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/021923s012lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "TRK Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Tovorafenib", "targets_moa": "RAF serine/threonine protein kinase inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710688", "http://www.sunesis.com/products-in-development/product/MLN2480.php", "5653214"], "ref_urls": ["http://europepmc.org/abstract/MED/5653214", "http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710688", "http://www.sunesis.com/products-in-development/product/MLN2480.php"]}, {"gene_symbol": "BRAF", "therapy_name": "Vemurafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/202429s000lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}], "error": null}
{"id": "F6.4-000001-P2", "family_id": "F6.4", "template_id": "f6_4_alternative_therapies_for_resistance_in_disease", "question": "Which treatments target resistance biomarkers for Erlotinib in Lung Cancer?", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t1:Therapy)\nWHERE (\n  toLower(t1.name) = toLower('Erlotinib')\n  OR any(s IN coalesce(t1.synonyms, []) WHERE toLower(s) = toLower('Erlotinib'))\n  OR toLower(t1.name) CONTAINS toLower('Erlotinib')\n)\n  AND toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol\nWHERE gene_symbol IS NOT NULL\nMATCH (t2:Therapy)-[r:TARGETS]->(tg:Gene)\nWHERE (\n  toLower(tg.symbol) = toLower(gene_symbol)\n  OR any(s IN coalesce(tg.synonyms, []) WHERE toLower(s) = toLower(gene_symbol))\n)\n  AND toLower(t2.name) <> toLower('Erlotinib')\nRETURN\n  gene_symbol,\n  t2.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "therapy_name": "Agerafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "BRAF Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}, {"gene_symbol": "BRAF", "therapy_name": "Belvarafenib", "targets_moa": "RAF serine/threonine protein kinase inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570", "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3000"], "ref_urls": ["https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570", "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3000"]}, {"gene_symbol": "BRAF", "therapy_name": "Dabrafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=803beaaa-33f9-48cc-9a95-c2e887e095b4#nlm34090-1"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4#nlm34090-1"]}, {"gene_symbol": "BRAF", "therapy_name": "Encorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}, {"gene_symbol": "BRAF", "therapy_name": "Pan-RAF Inhibitor LY3009120", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["25965804"], "ref_urls": ["http://europepmc.org/abstract/MED/25965804"]}, {"gene_symbol": "BRAF", "therapy_name": "Regorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Regorafenib Anhydrous", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Sorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/021923s012lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Sorafenib Tosylate", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/021923s012lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "TRK Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Tovorafenib", "targets_moa": "RAF serine/threonine protein kinase inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710688", "http://www.sunesis.com/products-in-development/product/MLN2480.php", "5653214"], "ref_urls": ["http://europepmc.org/abstract/MED/5653214", "http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710688", "http://www.sunesis.com/products-in-development/product/MLN2480.php"]}, {"gene_symbol": "BRAF", "therapy_name": "Vemurafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/202429s000lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}], "error": null}
{"id": "F6.4-000001-P3", "family_id": "F6.4", "template_id": "f6_4_alternative_therapies_for_resistance_in_disease", "question": "Find alternative therapies targeting resistance genes for Erlotinib in Lung Cancer.", "cypher": "MATCH (b:Biomarker)-[rel:AFFECTS_RESPONSE_TO]->(t1:Therapy)\nWHERE (\n  toLower(t1.name) = toLower('Erlotinib')\n  OR any(s IN coalesce(t1.synonyms, []) WHERE toLower(s) = toLower('Erlotinib'))\n  OR toLower(t1.name) CONTAINS toLower('Erlotinib')\n)\n  AND toLower(rel.effect) = 'resistance'\n  AND (\n    toLower(rel.disease_name) CONTAINS 'lung'\n  )\nOPTIONAL MATCH (b)-[:VARIANT_OF]->(g:Gene)\nWITH CASE WHEN b:Gene THEN b.symbol ELSE g.symbol END AS gene_symbol\nWHERE gene_symbol IS NOT NULL\nMATCH (t2:Therapy)-[r:TARGETS]->(tg:Gene)\nWHERE (\n  toLower(tg.symbol) = toLower(gene_symbol)\n  OR any(s IN coalesce(tg.synonyms, []) WHERE toLower(s) = toLower(gene_symbol))\n)\n  AND toLower(t2.name) <> toLower('Erlotinib')\nRETURN\n  gene_symbol,\n  t2.name AS therapy_name,\n  r.moa AS targets_moa,\n  coalesce(r.ref_sources, []) AS ref_sources,\n  coalesce(r.ref_ids, []) AS ref_ids,\n  coalesce(r.ref_urls, []) AS ref_urls\nLIMIT 100\n", "result": [{"gene_symbol": "BRAF", "therapy_name": "Agerafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "BRAF Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}, {"gene_symbol": "BRAF", "therapy_name": "Belvarafenib", "targets_moa": "RAF serine/threonine protein kinase inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570", "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3000"], "ref_urls": ["https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570", "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3000"]}, {"gene_symbol": "BRAF", "therapy_name": "Dabrafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=803beaaa-33f9-48cc-9a95-c2e887e095b4#nlm34090-1"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4#nlm34090-1"]}, {"gene_symbol": "BRAF", "therapy_name": "Encorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["DOI", "PubMed"], "ref_ids": ["10.1158/1538-7445.AM2012-3790", "23617957"], "ref_urls": ["http://cancerres.aacrjournals.org/content/72/8_Supplement/3790", "http://europepmc.org/abstract/MED/23617957"]}, {"gene_symbol": "BRAF", "therapy_name": "Pan-RAF Inhibitor LY3009120", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["25965804"], "ref_urls": ["http://europepmc.org/abstract/MED/25965804"]}, {"gene_symbol": "BRAF", "therapy_name": "Regorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Regorafenib Anhydrous", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Sorafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/021923s012lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Sorafenib Tosylate", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/021923s012lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "TRK Inhibitor", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["Expert", "FDA"], "ref_ids": ["REGORAFENIB", "label/2012/203085lbl.pdf"], "ref_urls": ["http://chembl.blogspot.co.uk/search?q=REGORAFENIB", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf"]}, {"gene_symbol": "BRAF", "therapy_name": "Tovorafenib", "targets_moa": "RAF serine/threonine protein kinase inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710688", "http://www.sunesis.com/products-in-development/product/MLN2480.php", "5653214"], "ref_urls": ["http://europepmc.org/abstract/MED/5653214", "http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710688", "http://www.sunesis.com/products-in-development/product/MLN2480.php"]}, {"gene_symbol": "BRAF", "therapy_name": "Vemurafenib", "targets_moa": "Serine/threonine-protein kinase B-raf inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2011/202429s000lbl.pdf"], "ref_urls": ["http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Afatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["fd638e5e-8032-e7ca-0179-95e96ab5d387"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387"]}, {"gene_symbol": "EGFR", "therapy_name": "Agerafenib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other"], "ref_ids": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"], "ref_urls": ["http://ignyta.com/wp-content/uploads/2015/11/ENA-2015-poster-RXDX-105.pdf", "http://ignyta.com/wp-content/uploads/2015/11/RXDX-105-ENA-Clinical-Poster.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Amivantamab", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["32414908"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/32414908/"]}, {"gene_symbol": "EGFR", "therapy_name": "Aumolertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["32916310", "33656275"], "ref_urls": ["http://europepmc.org/abstract/MED/32916310", "http://europepmc.org/abstract/MED/33656275"]}, {"gene_symbol": "EGFR", "therapy_name": "Brigatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "Other", "PubMed"], "ref_ids": ["http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf", "25888090"], "ref_urls": ["http://europepmc.org/abstract/MED/25888090", "http://www.ariad.com/AP26113", "http://www.ariad.com/pdf/Rivera_2012_AACR_POSTER_AP26113_noQRcode.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Canertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed"], "ref_ids": ["11706399", "12648472"], "ref_urls": ["http://europepmc.org/abstract/MED/11706399", "http://europepmc.org/abstract/MED/12648472"]}, {"gene_symbol": "EGFR", "therapy_name": "Cetuximab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"]}, {"gene_symbol": "EGFR", "therapy_name": "Dacomitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other", "PubMed"], "ref_ids": ["https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf", "18089823"], "ref_urls": ["http://europepmc.org/abstract/MED/18089823", "https://www.pfizer.com/files/news/esmo/dacomitinib_fact_sheet.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Duligotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["27843803"], "ref_urls": ["http://europepmc.org/abstract/MED/27843803"]}, {"gene_symbol": "EGFR", "therapy_name": "ERBB3 Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Erlotinib Hydrochloride", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Gefitinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41"]}, {"gene_symbol": "EGFR", "therapy_name": "Icotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed"], "ref_ids": ["22112293", "22446631", "23586056"], "ref_urls": ["http://europepmc.org/abstract/MED/22112293", "http://europepmc.org/abstract/MED/22446631", "http://europepmc.org/abstract/MED/23586056"]}, {"gene_symbol": "EGFR", "therapy_name": "Lapatinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808#section-13"]}, {"gene_symbol": "EGFR", "therapy_name": "Lazertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["34028784"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/34028784/"]}, {"gene_symbol": "EGFR", "therapy_name": "Mobocertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Naquotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed", "PubMed", "PubMed", "PubMed"], "ref_ids": ["28954786", "29386539", "29807396", "31227004"], "ref_urls": ["http://europepmc.org/abstract/MED/28954786", "http://europepmc.org/abstract/MED/29386539", "http://europepmc.org/abstract/MED/29807396", "http://europepmc.org/abstract/MED/31227004"]}, {"gene_symbol": "EGFR", "therapy_name": "Neratinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA", "PubMed", "PubMed"], "ref_ids": ["label/2017/208051s000lbl.pdf", "15715478", "26089701"], "ref_urls": ["http://europepmc.org/abstract/MED/15715478", "http://europepmc.org/abstract/MED/26089701", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Nimotuzumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["19584289"], "ref_urls": ["http://europepmc.org/abstract/MED/19584289"]}, {"gene_symbol": "EGFR", "therapy_name": "Osimertinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed", "PubMed", "PubMed"], "ref_ids": ["setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "24893891", "25271963"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "http://europepmc.org/abstract/MED/24893891", "http://europepmc.org/abstract/MED/25271963"]}, {"gene_symbol": "EGFR", "therapy_name": "Panitumumab", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2"]}, {"gene_symbol": "EGFR", "therapy_name": "Poziotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["21306821"], "ref_urls": ["http://europepmc.org/abstract/MED/21306821"]}, {"gene_symbol": "EGFR", "therapy_name": "Pyrotinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["Other"], "ref_ids": ["http://meetinglibrary.asco.org/content/146824-156"], "ref_urls": ["http://meetinglibrary.asco.org/content/146824-156"]}, {"gene_symbol": "EGFR", "therapy_name": "Rindopepimut", "targets_moa": "Epidermal growth factor receptor erbB1 vaccine antigen", "ref_sources": ["PubMed"], "ref_ids": ["28274144"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/28274144/"]}, {"gene_symbol": "EGFR", "therapy_name": "Rociletinib", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["24723450"], "ref_urls": ["http://europepmc.org/abstract/MED/24723450"]}, {"gene_symbol": "EGFR", "therapy_name": "TAK-788", "targets_moa": "Epidermal growth factor receptor erbB1 inhibitor", "ref_sources": ["FDA"], "ref_ids": ["label/2021/215310s000lbl.pdf"], "ref_urls": ["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf"]}, {"gene_symbol": "EGFR", "therapy_name": "Tarloxotinib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["PubMed"], "ref_ids": ["33355298"], "ref_urls": ["https://pubmed.ncbi.nlm.nih.gov/33355298/"]}, {"gene_symbol": "EGFR", "therapy_name": "Vandetanib", "targets_moa": "Epidermal growth factor receptor inhibitor", "ref_sources": ["DailyMed"], "ref_ids": ["setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"], "ref_urls": ["http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525#section-13"]}], "error": null}
